FORUM REVIEW ARTICLE

Neurotoxicity Linked to Dysfunctional Metal Ion Homeostasis and Xenobiotic Metal Exposure: Redox Signaling and Oxidative Stress

Carla Garza-Lombó^{1,2,*} Yanahi Posadas^{3,4,*} Liliana Quintanar,⁴
María E. Gonshebbat² and Rodrigo Franco¹

Abstract

Significance: Essential metals such as copper, iron, manganese, and zinc play a role as cofactors in the activity of a wide range of processes involved in cellular homeostasis and survival, as well as during organ and tissue development. Throughout our life span, humans are also exposed to xenobiotic metals from natural and anthropogenic sources, including aluminum, arsenic, cadmium, lead, and mercury. It is well recognized that alterations in the homeostasis of essential metals and an increased environmental/occupational exposure to xenobiotic metals are linked to several neurological disorders, including neurodegeneration and neurodevelopmental alterations.

Recent Advances: The redox activity of essential metals is key for neuronal homeostasis and brain function. Alterations in redox homeostasis and signaling are central to the pathological consequences of dysfunctional metal ion homeostasis and increased exposure to xenobiotic metals. Both redox-active and redox-inactive metals trigger oxidative stress and damage in the central nervous system, and the exact mechanisms involved are starting to become delineated.

Critical Issues: In this review, we aim to appraise the role of essential metals in determining the redox balance in the brain and the mechanisms by which alterations in the homeostasis of essential metals and exposure to xenobiotic metals disturb the cellular redox balance and signaling. We focus on recent literature regarding their transport, metabolism, and mechanisms of toxicity in neural systems.

Future Directions: Delineating the specific mechanisms by which metals alter redox homeostasis is key to understand the pathological processes that convey chronic neuronal dysfunction in neurodegenerative and neurodevelopmental disorders. *Antioxid. Redox Signal.* 28, 1669–1703.

Keywords: neurodegeneration, redox, essential metals, heavy metals, neurotoxicity

Introduction

MOST ELEMENTS in the periodic table are considered metals due to their propensity to lose electrons and react with molecular oxygen (O₂) to form oxides. Metals in biological systems may be broadly divided into four groups:

alkali and alkaline-earth metals, such as sodium (Na), potassium (K), magnesium (Mg), and calcium (Ca); essential transition metals, such as copper (Cu), manganese (Mn), iron (Fe), and zinc (Zn); and xenobiotic heavy metals such as mercury (Hg), lead (Pb), and cadmium (Cd). In addition, metalloids such as arsenic (As) are present in the

¹Redox Biology Center and School of Veterinary Medicine and Biomedical Sciences, University of Nebraska–Lincoln, Lincoln, Nebraska.

²Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, México.

Departamentos de ³Farmacología y de ⁴Química, Centro de Investigación y de Estudios Avanzados (CINVESTAV), Mexico City, México.

*Both these authors contributed equally to this work.

environment and have chemical and physical properties of both metal and nonmetal elements. Some authors include aluminum (Al) and selenium (Se) as metalloids. For simplicity, herein we will refer to metalloids as metals. Importantly, while essential metals participate in normal biological functions, alterations in their handling or their increased accumulation are well reported to exert neurotoxicity (Supplementary Table S1; Supplementary Data are available online at www.liebertpub.com/ars).

Prospective epidemiological studies have associated cognitive, motor, and behavioral alterations to environmental exposure to metals and metalloids (153, 158, 250, 371), effects that are exacerbated when environmental exposures occur chronically and during development (153, 158, 250). Long-term effects of either environmental metal exposure or alterations in metal homeostasis in the central nervous system (CNS) and peripheral nervous system (PNS) have been proposed to play a role in neurodegenerative disorders (379). Importantly, alterations in the cellular redox environment of the cell are central to the toxic effects of metals.

Previous reviews address the general role of metals in neurodegeneration, or the mechanisms by which metals produce oxidative stress or neurotoxicity (85, 86, 89, 163, 355). In this work, we present an integrated review on recent advances in (a) the metabolism of both essential and xenobiotic metals; (b) the mechanisms by which distinct metals determine or modify the cellular redox homeostasis; (c) the link between metal redox activity and function in neural systems; and (d) how alterations in metal homeostasis or intracellular/extracellular levels participate in neurotoxicity and neurodegeneration.

Overview of Oxidative Stress and Redox Homeostasis

Reactive species is a term used to describe compounds that can receive or provide a couple of electrons or one electron participating in nucleophilic, electrophilic, or redox metabolic reactions, respectively. Reactive oxygen species (ROS) are molecules derived from O_2 , an obligate component of aerobic organisms. The reduction of O_2 is one of the primary reactions that sustain aerobic life, yet it is also the main source for ROS. ROS include free ($\bullet$) and nonfree radical species such as hydroxyl radicals ($\bullet OH$), superoxide anion radicals ($O_2^{\bullet -}$), and hydrogen peroxide (H_2O_2). Reactive nitrogen species (RNS) contain both nitrogen (N) and O (oxygen atom), and thus can be categorized as ROS. RNS include nitric oxide ($NO\bullet$), nitrogen dioxide radical ($NO_2\bullet$), and peroxynitrite ($ONOO^-$) (120, 252).

A major source of intracellular ROS production are the mitochondrial electron transport complexes, primarily the one-electron reduction of O_2 to $O_2^{\bullet -}$ by complex I (ubiquinone: NADH oxidoreductase), by the semiquinone of ubiquinone (coenzyme Q), and by complex III (cytochrome bc1 complex or CoQH2-cytochrome c reductase). $O_2^{\bullet -}$ undergoes rapid dismutation into H_2O_2 through the action of superoxide dismutases (SODs). Three types of SODs exist in mammalian cells that use an essential metal as cofactor. Cu/Zn-dependent SOD1 and 3 are localized in the cytosol (SOD1), the extracellular space (SOD3) and to a lesser extent, in the inner membrane space of the mitochondria (SOD1). MnSOD (SOD2) is solely localized in the mitochondrial matrix. The transition metal (Cu or Mn) in the

active site of SODs is required for the breakdown of $O_2^{\bullet -}$ by catalyzing both the one-electron oxidation and one-electron reduction of separate $O_2^{\bullet -}$ to give the overall disproportionation reaction that produces O_2 and H_2O_2 . Binding of Zn to SOD1 or 3 is not essential for $O_2^{\bullet -}$ dismutation reaction but confers higher thermal stability to the proteins (64).

One to 2% of the total mitochondrial O_2 consumed is leaked and contributes to the formation of ROS. Usually, this occurs at a slow rate and can be counteracted by mitochondrial antioxidant systems, but in damaged or aged mitochondria, increased ROS formation occurs. $O_2^{\bullet -}$ and H_2O_2 fuel $\bullet OH$ formation through Fenton/Haber–Weiss reactions, where H_2O_2 oxidizes a redox-active metal (Fe or Cu) leading to the formation of $\bullet OH$. Then, the oxidized metal is reduced back by $O_2^{\bullet -}$ or other cellular reductants promoting metal-catalyzed free radical chain reactions (100, 120, 252).

Other sources of ROS are the nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidases (NOX), enzymes whose principal function is to generate $O_2^{\bullet -}$ or H_2O_2 . The formation of RNS begins with the synthesis of $NO\bullet$, catalyzed by nitric oxide synthases (NOSs), which are Fe dependent. Zn is an important structural element of NOS enzymes and is also known to inhibit their activity. $NO\bullet$ reacts with $O_2^{\bullet -}$ to produce $ONOO^-$, which is a strong oxidizing agent. Microsomes and peroxisomes are important sources of ROS due to the presence of NOX and NOS (302). In addition, ROS production can be mediated by the activity of enzymes such as xanthine oxidase (that contains an Fe-sulfur [S] cluster), the heme proteins cyclooxygenases, cytochrome P450 enzymes, lipoxygenases, and myeloperoxidases, as well as the protein folding machinery in the endoplasmic reticulum (ER) (96, 120, 252).

ROS/RNS act as signaling molecules affecting the stability, expression, function, and activity of a multiplicity of proteins controlling almost all cellular functions, including proliferation, cell survival, metabolism, and signaling. An adequate balance between the formation and elimination of ROS/RNS facilitates the signaling role of these reactive species. However, an imbalance between an increase in the steady-state levels of ROS/RNS and the ability of the cell to metabolize/detoxify them leads to a nonhomeostatic state referred to as oxidative stress. Oxidative stress results in the irreversible oxidative modification of biomolecules with the concomitant loss of function of proteins, damage to cellular organelles, and eventual cell death (96, 100, 252, 282). Polyunsaturated fatty acids are one of the preferred oxidation targets for ROS; particularly, free radicals that are potent initiators of lipid peroxidative chain reactions. Lipid peroxidation products, including malondialdehyde (MDA) and 4-hydroxy-2-nonenal (HNE), can react further with DNA bases and proteins (83). DNA bases are also susceptible to direct oxidation by free radicals that can cause mutations as well as deletions in both nuclear and mitochondrial DNA (328).

Protein oxidation can be a reversible or irreversible phenomenon depending on the type of modification, ROS involved, and the extent of oxidation. Tyrosine (Tyr) nitration, protein carbonylation, and protein crosslinkage generated by adduct formation between oxidized proteins, lipid peroxides, or glycative products are irreversible modifications that promote a loss of function, aggregation, and degradation of the targeted protein, and in some cases, the formation of toxic by-products (71). In contrast, reversible oxidative modifications

in the sulfur-containing amino acids methionine (Met) and cysteine (Cys) act as sensors and transducers of ROS/RNS-mediated signaling. Thiol-based oxidoreductases thioredoxins (Trxs), glutaredoxins (Grxs), and Met sulfoxide reductases reduce such modifications acting as the OFF-switch for redox signaling processes (101, 160). On the contrary, both Trxs and peroxiredoxins (Prxs) have been proposed to act as redox sensors, buffers, and relays for H_2O_2 - and $\text{NO}^\bullet$ -mediated signal transduction (46, 195, 268, 323). Cys are also targeted by electrophiles generating irreversible modifications, which are thought to be a primary mechanism of toxicity by xenobiotics (193).

Cells are equipped with enzymatic and nonenzymatic antioxidant systems to counteract the toxic effects of ROS/RNS and maintain redox homeostasis (96, 100, 120, 252). The reducing power of glutathione (GSH) is essential for the detoxification of peroxides by GSH peroxidases (GPX) with the resultant conversion of GSH to GSH disulfide (GSSG). GSSG is reduced back by GSH reductase (GR) in an NADPH-dependent manner (105). Catalases also detoxify peroxides but their localization is primarily restricted to peroxisomes. Other endogenous nonenzymatic antioxidants include uric acid, lipoic acid, and ubiquinol (or reduced coenzyme Q), and those obtained from the diet, such as vitamins and flavonoids (96, 100, 120, 252).

The CNS is particularly sensitive to oxidative damage, from which neurons and oligodendrocytes seem to be more susceptible than astrocytes and microglia. The basis for this increased sensitivity is linked to the high levels of O_2 consumption (and electron leakage as a consequence), the low levels of antioxidant defenses when compared to other cells, and the abundance of lipids or fatty acids (262, 295).

Higher levels of endogenous antioxidants and antioxidant systems in astrocytes are explained by the activation of the nuclear factor erythroid-2-related factor 2 (Nrf2) transcription factor (314). Nrf2 recognizes antioxidant response elements to trigger the transcription of antioxidant systems. The ubiquitin ligase Kelch-like ECH-associated protein 1 (Keap1) negatively regulates Nrf2 signaling by inducing its ubiquitination and degradation. Upon modification of specific Cys residues within Keap1 by oxidants or electrophiles (including metals), Nrf2 is released from Keap1 and translocates to the nucleus to induce gene expression dependent on antioxidant response elements (ARE). Nrf2 signaling in neurons has been reported to be epigenetically silenced (27), and induction of the Nrf2 pathway does not seem to be able to promote antioxidant protection (148). Astrocytes also have higher levels of NADPH and glucose 6-phosphate dehydrogenase (G6PD) (109). In contrast, antioxidant genes in neurons seem to be transcriptionally regulated, independent from Nrf2 by synaptic activity, through the triggering of the activating transcription factor 4 (ATF4) and the activator protein 1 (AP-1) (23, 177). Furthermore, while both neurons and astrocytes can synthesize GSH, neurons depend on the supply of GSH precursors *via* GSH efflux (13, 26).

Neurotoxicity of Metals and Metalloids

Neurotoxicity is defined as a damaging effect on the nervous system caused by a biological or chemical agent. The neurotoxic effects of chemicals are the result of a series of

events that include the following: the entry and/or changes in the distribution of a chemical into the brain, interactions with specific cellular targets (neurons and glia), and the initiation of biochemical changes, resulting in structural and functional changes of the nervous system (270). Environmental neurotoxicants include organic and inorganic chemical compounds, such as heavy metals, organic solvents, and cytotoxic substances that can also contain heavy metal mixtures (*e.g.*, pesticides, cigarette smoke, diesel exhaust particles.). The neurotoxic effect of environmental agents is determined by their chemical composition, metabolic function, and pathological consequence, differing widely according to the brain region targeted and the mechanism(s) of action (270).

Essential Metals

Micronutrients are defined by their essentiality and very limited quantity in humans, where their deficiency results in the impairment of biological functions (103, 205). Some metals are essential for the maintenance of cellular homeostasis. Essential metals display important roles as signaling agents or cofactors and, in particular, as activators or redox system components (Supplementary Table S1) (103, 205). Traditionally, cellular osmotic balance and signaling (including synaptic communication and excitability) are associated with nontransition metal ions, such as Na^+ , K^+ , and Ca^{2+} , which form complexes with proteins using low-affinity binding sites, are found at high concentrations, and move quickly across cellular compartments. On the contrary, transition metal ions are known as catalytic cofactors or structural elements in enzymes. Transition metals are present in lower concentration ("trace elements") and are usually coordinated to proteins at high-affinity binding sites. In the last decade, a role for Zn^{2+} ion as a second messenger has been recognized; however, the role of redox-active metals, such as Cu, Fe, and Mn, in cellular signaling is less explored.

Cu, Fe, and Mn are cofactors of many enzymes that catalyze redox reactions. Although the high reactivity of these metals is essential for life, they can also be involved in uncontrolled redox reactions associated with oxidative stress and cellular damage. Hence, a highly conserved network of proteins strictly regulates the homeostasis of redox-active metal ions, by controlling their uptake, intracellular distribution, storage, and export (205). In the following sections, we describe how brain homeostasis of redox reactive metal ions requires close communication between the blood-brain barrier (BBB), neurons, astrocytes, oligodendrocytes, and microglia. The cases where metal trafficking is tightly linked to the cellular redox environment are highlighted, while the potential role of metal redox cycling in redox signaling is also discussed. Finally, for each essential metal ion, we review how the disruption of its homeostasis may cause two major features associated with neurodegenerative diseases: dysfunction of metalloproteins and aberrant metal-protein interactions that can lead to protein aggregation and uncontrolled ROS production.

Copper

Cu is present in biological systems as Cu^+ (cuprous ion) and Cu^{2+} (cupric ion) (Supplementary Table S1). Cu is a redox-active metal and a cofactor of many enzymes involved in cellular respiration, radical detoxification, as well as

biosynthesis of neurotransmitters, neuropeptides, and hormones. For example, Cu is required as cofactor of several important enzymes in the brain, such as peptidylglycine monooxygenase (PHM), dopamine β -monooxygenase (DBM), tyrosinase (TYR), and cytochrome C oxidase (COX). Cu can activate O_2 for reduction and although its high reactivity with O_2 is essential for life, if uncontrolled it can promote oxidative stress and cellular damage. Cu^+ can react with H_2O_2 to produce highly reactive $\bullet OH$. Cu also induces microglial activation and mitochondrial ROS formation (137).

The control of Cu homeostasis in the brain requires a close interrelationship between the BBB, neurons, and astrocytes (300) (Fig. 1). Astrocytes regulate the properties of the BBB, which is the entry point for Cu into the brain from the blood stream, where Cu is bound to albumin or ceruloplasmin (Cp) (58) (Fig. 1a). At the same time, neurons require Cu as a cofactor and neuromodulator, while astrocytes are key players in synaptic transmission and Cu homeostasis (58). The Cu trafficking machineries of the BBB endothelial cells, neurons, and astrocytes resemble those of other extensively studied mammalian cells (Fig. 1a–c). Extracellular Cu is primarily transported into cells as Cu^+ via the Cu transporter 1 (CTR1) (58). Cu^{2+} reduction to Cu^+ , and Cu uptake from Cp via CTR1, has been proposed to involve a reduction step

but no Cu^{2+} reductase has been identified (281). CTR1-independent mechanisms have also been proposed. The divalent metal transporter 1 (DMT1) seems to play a compensatory role for Cu uptake under certain conditions such as in the absence of CTR1 or under low Fe conditions (147, 231). Interestingly, DMT1 loss promotes brain Cu accumulation and oxidative stress (122). Other potential candidates recently proposed to mediate Cu uptake are the Zrt (Zn-regulated transporter)- or Irt (Fe-regulated transporter)-like protein 4 (ZIP4) (11, 29).

Intracellular Cu distribution depends on the relative concentration and metal affinity of chaperones or chelators (18) (Fig. 1b, c). The antioxidant protein 1 (Atox1), the Cu chaperone for superoxide dismutase 1 (CCS1), and GSH have been proposed to take Cu^+ from CTR1 (197). Chaperones not only bind Cu but they also deliver it to specific targets. CCS1 transfers Cu to SOD1, where its reactivity with O_2 is required for SOD1 maturation via the formation of a disulfide bridge (17). Copper chaperones COX19 and COX17 deliver Cu to the COX assembly proteins (SCO1 and SCO2) and COX11. Finally, Atox1 transports Cu to the ATPase copper transporting alpha (ATP7A) and beta (ATP7B) in the secretory pathway, where cuproenzymes such as SOD3 are metalized (Fig. 1b, c). Upon an excess in cytosolic Cu levels, vesicles in

FIG. 1. Cu homeostasis in the brain and its redox control. Regulation of Cu homeostasis is a complex process requiring intercommunication between endothelial cells of the BBB, astrocytes, and neurons. These three types of cells have the same protein machinery as other mammalian cells: CTR1 and DMT1 for Cu uptake; Atox1, CCS1, and GSH for Cu delivery to ATP7(A/B), SOD3, and MT, respectively; COX17 and COX19 for Cu delivery to mitochondria, where SCO1, SCO2, and COX11 load Cu into COX; while ATP7 (A/B) participates in Cu export through the secretory pathway (a–c). (a) Cp- and albumin-bound Cu enters into the brain by crossing endothelial cells of BBB, which are in tight communication with astrocytes. (b) Astrocytes serve as an interface to deliver Cu to (c) neurons. (d) Recently, a redox control of Cu efflux was elucidated in neurons during differentiation: the redox state of Atox1 controls Cu delivery to the secretory pathway. ATP7A, ATPase copper transporting alpha; ATP7B, ATPase copper transporting beta; Atox1, antioxidant protein 1; BBB, blood-brain barrier; CCS1, copper chaperone for superoxide dismutase 1; COX, cytochrome C oxidase; Cp, ceruloplasmin; CTR1, copper transporter 1; Cu, copper; DMT1, divalent metal transporter 1; Glu, glutamate; GSSG, glutathione disulfide; GSH, glutathione; MT, metallothionein; SCO, cytochrome c oxidase assembly protein; SOD, superoxide dismutase.

the secretory pathway are loaded with Cu and trafficked to the plasma membrane, where Cu is released into the extracellular space (196, 197).

Strikingly, although GSH has a lower affinity for Cu, compared to Atox1 and CCS1, the rate of Cu entry into the cell *via* CTR1 is affected by GSH, but not by Atox1 or CCS1 depletion, likely due to the higher concentration of GSH (208). Thus, GSH is the most important cytosolic first acceptor of Cu from CTR1, providing a tight link between cellular Cu uptake and cellular redox homeostasis. GSH in turn is known to transfer Cu ions to metallothioneins (MTs), small Cys-rich proteins that play a major role as scavengers for metal ions (93) (Fig. 1b, c). Three distinct isoforms of MTs are expressed in the human brain. MT-I, MT-II, and MT-III are found in astrocytes, while MT-III is the main isoform expressed in neurons. MTs can be secreted, playing a crucial role in modulating Cu homeostasis and protecting the cell from oxidative damage (299).

Chaperones use Cys residues to coordinate Cu⁺ in their reduced state. Thus, Cys oxidation affects Cu dynamics. Atox1 coordinates Cu using a CysXXCys motif that can form a disulfide bond, which can be reduced directly by GSH or by Grx1 in a GSH-dependent manner (Fig. 1d) (41, 127). During neuronal differentiation, the GSH/GSSG ratio increases promoting a more reductive environment, which in turn reduces Cys residues at the Cu binding site of Atox1. These events enable Cu transport from Atox1 to ATP7A/B and enhance Cu availability to load the active sites of newly synthesized cuproenzymes (128) (Fig. 1d). After neuronal differentiation, both Cu and MT-III levels increase (249).

The recent development of fluorescent sensors has revealed new important roles of intracellular Cu in neuronal activity (78); for example, in the spine neck of hippocampal neurons, Cu is essential for the control of the dendritic actin cytoskeleton (269). Cu export by ATP7A has been reported to be triggered by the activation of glutamate (Glu)/N-methyl-D-aspartate receptors (NMDARs) (301) (Fig. 2a). At the synapse, Cu can modulate many neurotransmitter receptors (66). For example, Cu inhibits NMDAR activity by Cys nitrosylation, a neuroprotective mechanism associated with neuronal plasticity that requires the participation of the cellular prion protein (PrP^C) (110) (Fig. 2b). Accordingly, selective depletion of ATP7A in neurons and glia increases the susceptibility to NMDA seizures (132).

Cu trafficking at the synapse is complex and involves several Cu binding proteins, such as the membrane-bound PrP^C, the amyloid precursor protein (APP), and the amyloid beta (A β) peptide from neurons, or the neurokinin B (NKB) peptide from astrocytes (Fig. 2). PrP^C has several Cu binding sites and it might be involved in Cu sensing and transport into neurons (Fig. 3a). During synaptic transmission, the extracellular Cu concentration may reach ~100 μ M. Cu binding to PrP^C induces its endocytosis, possibly contributing to Cu delivering into the cytosol (263). APP has been reported to regulate Cu efflux, as the APP knockout mice display higher levels of Cu in the brain and in neurons, while APP overexpression leads to decreased intracellular Cu concentrations (28, 330, 375). In contrast, A β peptides produced from the proteolytic cleavage of APP have been proposed to act as Cu scavengers (264), particularly those cleaved to yield 4–40 peptides that have higher affinity for Cu and make up to 50% of the A β in plaques (374). NKB has been suggested to

compete for Cu from PrP^C and transport it into astrocytes by endocytosis (Fig. 2c) (308). PrP^C and A β contain intrinsically disordered regions with Cu binding sites that have the capacity to adopt different Cu coordination modes, some of which have been proposed to activate O₂ and produce ROS (Fig. 3a) (184, 350).

A dysfunction in Cu homeostasis is reported to alter neuronal function and lead to disease progression, including neurodegeneration (Supplementary Table S1). Menkes disease and Wilson disease are caused by mutations or partial deletions in *ATP7A* and *ATP7B*, respectively. These Cu transporters have different patterns of expression in the CNS, explaining the distinct pathological features of each disease. ATP7B is found in the visual cortex, anterior cingulate cortex, caudate, putamen, substantia nigra (SN), and cerebellum. ATP7A is detected in astrocytes and neurons from the hippocampus and cerebellum, the BBB and choroid plexus, and during neural development (338). Wilson patients display parkinsonism, underscoring the importance of Cu homeostasis in the motor controlling systems. On the contrary, the ubiquitous expression of ATP7A has challenged mechanistic investigations in Menkes disease. However, a recent study shows that depleting ATP7A in neurons and glia does not lead to neurodegeneration, but to an increased susceptibility to NMDA seizures (132), underscoring its neuroprotective role as described above (Fig. 2a,b). Although neurodegeneration is clearly linked to alterations in Cu homeostasis in Menkes and Wilson diseases, the mechanisms are still unknown.

Neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), Parkinson's disease (PD), and Alzheimer's disease (AD) have been associated with alterations in Cu homeostasis, but a link to specific genetic alterations in Cu transport or handling is missing (Supplementary Table S1). These neurodegenerative diseases are associated with the formation of amyloid aggregates composed of proteins that are either a Cu-dependent antioxidant enzyme, such as SOD1 in ALS, or Cu-binding proteins, such as A β and α -synuclein in AD and PD, respectively.

ALS is characterized by the degeneration of motor neurons, and mouse models show increased intracellular Cu levels and the formation of protein aggregates composed of SOD1 and Cu transport proteins such as Ctr1, CCS, Atox1, and Cox17 (344, 346). SOD1 aggregation has been associated with an alteration in protein stability, which is impacted by metallation and Cu-dependent dimerization. Although SOD1 plays an important role in clearing O₂^{•-}, studies have demonstrated that the mechanism is likely other than the alteration in the antioxidant capacity of SOD1 (312). Increased intracellular Cu levels have been reported in ALS models (346). Consistently, Cu chelators or MT-I overexpression extend the life span and slow disease progression of the *SOD1* (G93A) ALS mouse model (345).

HD is an autosomal dominant genetic disorder caused by polyglutamine (polyQ) repeat expansions near the N-terminus of the huntingtin (Htt) protein. HD is characterized by movement dysfunction, psychiatric and cognitive alterations linked to the degeneration of striatal spiny neurons. Cu accumulation in the striatum of HD transgenic mice has been reported (102). Mutant Htt forms toxic aggregates, but the mechanisms of toxicity are still unclear. A putative Cu binding site in Htt involving Met8 and His82 has

FIG. 2. Cu at synapse and redox signaling. (a) After activation of NMDAR, Cu is released at the synapse through the secretory pathway. Several Cu binding proteins are present in the synaptic cleft, including PrP^C, APP, Aβ peptides, and NKB. (b) The Cu-PrP^C interaction is particularly important for the modulation of NMDAR activity *via* S-nitrosylation. In turn, NO production is dependent on the activation of NMDAR and its interaction with nNOS through the PSD-95. (c) While NKB can assist Cu uptake into astrocytes, Cu distribution among Cu-binding proteins at the synapse likely depends on their relative concentration and affinities for Cu. (d) On the contrary, α-synuclein is an important presynaptic Cu-binding protein found in neurons; it is an IDP that can interact with membranes when it acquires α-helix structure at N-terminal region. Interestingly, Cu⁺ binding to the N-Terminal of α-synuclein enhances its α-helical conformation. Aβ, amyloid beta; APP, amyloid precursor protein; Cu⁺, cuprous ion; IDP, intrinsically disordered protein; NKB, neurokinin B; NMDAR, glutamate/N-methyl-D-aspartate receptor; nNOS, neural nitric oxide synthetase; PrP^C, cellular prion protein; PSD-95, postsynaptic density protein 95.

been identified, and this interaction promotes polyQ aggregate formation (102, 381), which is reduced by MT-III overexpression (123).

PD is characterized by the degeneration of dopaminergic neurons in the SN, which are rich in Cu. PD patients show decreased Cu content in the SN (70) without changes in Cu levels in serum, plasma, and cerebrospinal fluid (CSF) (203). Accordingly, decreased levels of CTR1 (70) have been reported in the SN, while MT-I and MT-II levels in active astrocytes are increased, reflecting a glial response to the loss of Cu homeostasis in PD (226). In contrast, occupational exposure to Cu has been linked to an increased risk to develop PD (115).

The accumulation of intracellular protein inclusions (Lewy bodies), where α-synuclein is the main protein component,

is another hallmark of PD (362). α-Synuclein is a small intrinsically disordered protein (IDP) enriched in presynaptic terminals and nucleus that can interact with cytoskeleton components and lipid membranes (170). IDPs are proteins that can adopt different conformations, and thus respond to changes in their biochemical environment. This property allows them to engage in interactions with multiple protein targets (23). Cu²⁺ and Cu⁺ ions are capable of binding to α-synuclein at three different sites (20, 33, 228, 361) (Fig. 3a). Interestingly, the H50Q SNCA/α-synuclein mutation linked to hereditary PD abolishes one Cu binding site altering Cu-induced α-synuclein aggregation (361). Moreover, Cu binding to the high-affinity Cu-binding site at the N-terminal region of α-synuclein accelerates its amyloid aggregation

FIG. 3. Structural features and redox properties of relevant metal-protein complexes in neurodegenerative diseases. (a) Cu can interact with PrP^C, A β , and α -synuclein. PrP^C has three coordination sites: *histidine* (His) His96, His111, and an octarepeat. Cu^{2+} coordination to His96 and His111 yields very similar complexes different to those generated upon Cu^{+} binding to His111. The octarepeat region coordinates up to four Cu^{2+} ions depending on the Cu^{2+} /PrP^C stoichiometric ratio. At low Cu:protein ratios, four His residues coordinate Cu^{2+} , while at high ratios each His can bind one Cu^{2+} ion. The different coordination chemistry of these Cu-PrP^C complexes is reflected in their redox properties. Similarly, Cu^{2+} coordination to A β (1–40/42) yields two different coordination modes that display different redox properties. Recently, coordination to A β (4–40/42) has also been described; this site displays higher affinity for Cu^{2+} than A β (1–40/42), and it yields a redox silent complex. On the contrary, nonacetylated α -synuclein has two high-affinity binding sites for Cu^{2+} : site one involving residues at the N-terminal, and site two at His50. Acetylation of α -synuclein, as described to occur *in vivo*, abolishes Cu^{2+} binding at site 1, although both forms of α -synuclein can bind Cu^{+} . (b) Fe^{2+} can interact with A β , but the redox properties of Fe-A β complexes remain unclear. Interestingly, recent studies propose that heme can bind to A β , yielding a heme (Fe)-A β complex with peroxidase activity. (c) Finally, Zn^{2+} can bind to the octarepeat region of PrP^C and with A β . Cu²⁺, cupric ion; Fe, iron; Fe²⁺, ferrous; Zn, zinc.

in vitro (20, 33); although this effect is abolished in acetylated α -synuclein (234), which is found in Lewy bodies (10).

While several studies have suggested that Cu-induced aggregation of α -synuclein is directly linked to its neurotoxicity, recent studies suggest a lack of correlation between protein aggregation and cytotoxicity (361); in fact, it has been demonstrated that α -synuclein potentiates the toxicity of Cu in dopaminergic cells in the absence of enhanced ac-

cumulation of protein aggregates (8). Clearly, further investigations are needed to completely understand the structural impact of Cu- α -synuclein interactions and their role in PD. On the contrary, acetylation and Cu^{+} binding to α -synuclein are two synergistic events that turn the intrinsically disordered N-terminal region into an α -helix conformation (228) (Fig. 2d), which displays higher affinity for membranes (75). These observations suggest a potential link between Cu^{+} - α -

synuclein interactions and the proposed function of α -synuclein in vesicle trafficking; a link that might be perturbed in PD.

Different redox modifications of α -synuclein are found in Lewy bodies, including Met oxidation, Tyr nitration (67), and formation of di-Tyr-linked α -synuclein dimers. Cu^+ - α -synuclein complexes have been implicated in these modifications, as they are capable of activating O_2 , leading to Met oxidation and di-Tyr bond formation (5, 227) (Fig. 3a). In contrast, a recent report suggests that Cu^+ complexes with oligomeric or fibrillar α -synuclein reduce metal-catalyzed ROS formation (264). Cu has also been shown to potentiate oxidative damage induced by the dopamine (DA) analog 6-hydroxydopamine (63). Cu also interacts with the early-onset PD recessive genes (protein) *PARK7* (DJ-1) and *PARK2* (Parkin). Cu binding to DJ-1 protects against metal toxicity, possibly acting as a chaperone for SOD1 (35, 114); while Parkin mutations have been reported to increase the cytotoxic effect of heavy metals, including Cu (1).

AD is a neurodegenerative disease associated with the degeneration of hippocampal and cortical neurons and eventual loss of memory and progressive dementia (326). Decreased levels of Cu are found in AD brains (42), while the total Cu content and labile nonprotein-bound Cu fraction are increased in the plasma of AD patients (325). Interestingly, polymorphisms in *ATP7B* have been linked to AD (326). AD is associated with the formation of extracellular amyloid plaques composed of Cu bound to A β peptides 1–40 and 1–42 fragments produced by cleavage of the APP, as well as N-truncated forms 4–40 and 4–42, and to a lesser extent 11–40/42 (210, 273, 364). The Cu binding features of A β 4–40/42 and 11–40/42 are different from those of 1–40/42, leading to the formation of Cu-A β complexes with distinct redox properties (Fig. 3a) (229). Different aggregation properties have also been described, as illustrated by the faster fiber assembly rate of A β 11–40/42 when compared with 1–40/42 (21). Substoichiometric Cu^{2+} concentrations trigger A β aggregation through a different pathway that involves the formation of oligomers more neurotoxic than those generated by the peptide alone (25, 204). On the contrary, the redox activity of Cu-A β complexes has also been proposed to lead to the generation of ROS (52, 214), but contradictory results exist as well (264). Interestingly, interaction of Cu with N-truncated 4–40 and 4–42 peptides yields redox-inactive Cu-A β complexes (229, 350). A dysfunction in Cu homeostasis in AD is also evidenced by decreased levels of MT-III (390). MTs are capable of exchanging Cu^{2+} with A β 1–40/42, reducing Cu and stabilizing it. This Cu exchange by MTs has been proposed as a redox-silencing mechanism that prevents ROS formation by Cu-A β complexes (223).

The impact of dysfunctional Cu homeostasis in AD might go beyond the neurotoxicity of Cu-A β complexes. APP, whose mutations are associated with AD, is a type 1 transmembrane protein that displays three Cu binding sites in its extracellular domain (22, 140). One Cu-binding site is located in the growth factor-like domain, and has been implicated in Cu-induced dimerization of APP, a process that would be important in cell adhesion and signaling (22). Cu was found to induce APP phosphorylation at Thr668 promoting its localization to the axonal membrane, suggesting an important link between Cu and APP functions at the synapse that might be perturbed in AD. A β peptides can also interfere with Cu-PrP^C interactions implicated in the regu-

lation of NMDAR activity (Fig. 2b) (389). In addition, Cu has been reported to promote the degradation of the low-density lipoprotein receptor-related protein 1 (LRP1) *via* Tyr nitration and proteasomal degradation, which was linked to a decrease of A β clearance and its resultant accumulation in brain vasculature (319). Clearly, Cu plays important roles in neuromodulation and signaling processes, which would be perturbed in AD.

Iron

Fe is found in biological systems primarily as ferrous (2+) and ferric (3+) ions (Supplementary Table S1). Fe is a redox-active metal involved in several redox reactions that catalyze the formation of ROS. Fe is tightly bound to Fe storage and transport proteins, while <5% is present as labile redox-active Fe bound to low-affinity molecules. Fe is required as cofactor of several important enzymes for respiration and synthesis of neurotransmitters, including tryptophan hydroxylase (serotonin) and Tyr hydroxylase (norepinephrine and DA), cholesterol, and fatty acids; the latter particularly important for nerve myelination (161, 342). Electron transfer in many Fe enzymes, including the mitochondrial respiratory complexes, is facilitated by heme and Fe/S clusters (291). Fe is also important as cofactor for peroxidases and catalases, which are important for cellular redox homeostasis (6).

Fe is heterogeneously distributed in the brain; it is highly concentrated in the SN, hippocampus, striatum, interpeduncular nuclei (125), and myelin (329) (Supplementary Table S1). Fe homeostasis is regulated by communication between the BBB and astrocytes. In the blood stream, Fe^{3+} is found coordinated to transferrin (Tf) or ferritin (Ft), and as heme. Fe uptake into the BBB can occur by two pathways: (a) by direct transport of Fe^{2+} into the cytosol *via* DMT1; or (b) by endocytosis of Tf-bound Fe^{3+} *via* the Tf receptor (TfR), where the low pH of the endosome causes the release of Fe^{3+} from Tf. In both cases, Fe^{3+} is reduced to Fe^{2+} by the duodenal cytochrome b (Dcytb) or by the six transmembrane epithelial antigen of the prostate 2 (Steap2) ferrireductases and then transported by DMT1 (Fig. 4a) (215, 218).

Fe efflux from endothelial cells to the interstitial space occurs *via* the coordinated activity of the Fe^{2+} transporter ferroportin (Fpn) and the Cu-dependent ferroxidases hephaestin (Hp) and soluble ceruloplasmin (sCp), which oxidize Fe^{2+} to Fe^{3+} . Astrocytes regulate the release of Fe from BBB by either secretion of sCp, which stimulates Fe release, or by production of hepcidin, a peptide that induces internalization and ubiquitination of Fpn and thus, decreased Fe efflux (216). Astrocytes also express a glycosylphosphatidylinositol (GPI)-anchored form of Cp, which interacts with Fpn and participates in Fe efflux (Fig. 4a) (144). In general, oligodendrocytes, astrocytes, microglia, and neurons have the same machinery for Fe efflux, involving the concerted action of Fpn with Cp or Hp (60).

The mechanisms of Fe uptake differ between brain cell types. Fe, Tf, and Ft are primarily found in oligodendrocytes (61). Most Tf in the brain is synthesized and secreted by oligodendrocytes as Fe-free Tf or apo-Tf and is required for Fe mobilization within the interstitial fluid brain (87). Although oligodendrocytes and astrocytes can accumulate high levels of Fe, they do not express TfR. Fe uptake into

FIG. 4. Fe transport and redox signaling. (a) Fe transport across the BBB occurs *via* DMT1 or by endocytosis of Tf- or Ft-bound Fe^{3+} ; followed by Fe release *via* the concerted action of Fpn with a ferroxidase, either Hp or sCp. Astrocytes modulate Fe transport through the production of sCp, sAPP, and hepcidin. sAPP stabilizes Fpn, while hepcidin induces its internalization. (b) Mitochondria are the organelles with highest demand of Fe. Although Fe transport into mitochondria is not fully understood, the recently demonstrated interaction between mitochondria and TfR-containing endosomes supports the “kiss and run” hypothesis. Inside the mitochondria, Fe crosses the inner membrane by Mfn2. (c) In hippocampal neurons, NMDAR activation induces Ca^{2+} entry and $\text{NO}^{\bullet}$ production by nNOS, causing S-nitrosylation of Dexas1, which in turn induces Fe uptake through DMT1 and TfR. (d) Increased intracellular Fe also induces H_2O_2 production, inducing Ca^{2+} release from ER *via* RyR, which is important for neuronal plasticity. Dexas1, Ras-related dexamethasone induced 1; ER, endoplasmic reticulum; Fe^{3+} , ferric; Fpn, ferroportin; Ft, ferritin; H_2O_2 , hydrogen peroxide; Hp, hephaestin; Mfn2, mitoferrin-2; $\text{NO}^{\bullet}$, nitric oxide; PAP7, peripheral benzodiazepine receptor-associated protein 7; RyR, ryanodine receptor; sAPP, soluble fragment of APP; sCp, soluble ceruloplasmin; Tf, transferrin; TfR: transferrin receptor.

oligodendrocytes has been recently proposed to involve the internalization of H-Ft by a mucin-domain containing protein (Tim-2) (343). In astrocytes, ascorbate-dependent Fe^{2+} uptake is mediated by DMT1 (167) and transient-receptor potential channels (265).

In neurons, the mechanisms involved in Fe uptake are still unclear. DMT1 is found in human neurons and its expression levels are negatively regulated by Fe exposure *via* ubiquitination and degradation (134). However, DMT1 seems to colocalize in cytoplasmic vesicles with TfR and to primarily contribute to Tf-bound Fe uptake (232, 266). The ZIP8 and ZIP14 members of the ZIP family of metal transporters have also been demonstrated to mediate Fe^{2+} uptake (188) and to be expressed in the brain (113). A recent report demonstrates that ZIP8 at the plasma membrane is the primary transporter involved in non-Tf-bound Fe into neurons (145).

In brain cells, the ferrireductases Dcytb and stromal cell-derived receptor, SDR2, are expressed in astrocytes (192, 351), while SDR2 and Steap2 are found in neurons (145). In all cases, it is important to note that Fe uptake and efflux always require redox cycling between Fe^{2+} and Fe^{3+} oxidation states.

Cytosolic Fe is stored by Ft, which is a protein complex formed by 24 subunits of heavy-ferritin (H-Ft) and light-ferritin (L-Ft) chains. Ft genes are regulated by Nrf2 (272).

While H-subunits have ferroxidase activity and participate in Fe uptake, L-subunits are involved in Fe mineralization and long-term storage. Ft can store ~ 4500 Fe ions in its core. However, the mechanism by which Fe is released from Ft remains unclear (47). Although Fe is mainly stored in the cytosol, mitochondria are the organelles with the highest Fe demand, as they require Fe-S clusters and heme groups for electron transfer during respiration. Similarly, mitochondria are also considered the main sources of ROS under physiological conditions. Therefore, mitochondrial Fe homeostasis must be tightly regulated to prevent uncontrolled ROS production.

The mechanism(s) involved in mitochondrial Fe uptake are still unclear. Fe is delivered by a direct “kiss and run” interaction between the endosomes containing Tf-bound Fe and mitochondria (69). Subsequently, the metal crosses the inner membrane *via* the Fe importer mitoferrin-2 (Mfn2) (Fig. 4b). In the mitochondrial matrix, Fe is either used for the biogenesis of prosthetic groups, Fe-S clusters, or heme, or it is stored by mitochondrial ferritin (FtMt), which is homologous to H-Ft, and it displays the same Fe uptake efficiency but lower ferroxidase activity. Fe distribution between mitochondria and cytosol depends on FtMt expression and the export of Fe prosthetic groups (106, 176).

Heme is a component of globins, a superfamily of heme-containing proteins involved in binding and/or transporting O_2 , and a cofactor for cytochromes, catalase, NOX, NOS, and myeloperoxidase, which is also found in microglia (59, 151, 198). Hemoglobin (Hb) is involved in O_2 , NO, and carbon dioxide (CO_2) transport in cells of erythroid lineage, but Hb α and β transcripts have been found in dopaminergic neurons, oligodendrocytes, and cortical or hippocampal astrocytes as well (32). Brain Hb levels are altered during neurodegeneration (94), but their functional consequences are unclear. Neuroglobin is another globin expressed in the CNS and PNS and found in both neurons and astrocytes. Neuroglobin has a higher affinity for O_2 than Hb and exerts a protective effect against oxidative and ischemic insults (7, 43, 81, 179, 331, 368). Oxidative stress has the potential to release heme from Hb, and labile heme can induce oxidative damage *via* Fenton reactions or NOX activation (165, 239). Heme oxygenases (HOs) catalyze heme degradation. HO-1 transcription is induced by oxidative stress, inflammation, hypoxia, and metal exposure, while HO-2 is constitutively expressed. HO activity has both antioxidant and pro-oxidant effects that relate to the ability of the cell to detoxify labile Fe released from heme (286, 369).

Cellular Fe trafficking is controlled by the iron regulatory proteins (IRP) IRP1 and IRP2 which regulate translation of proteins involved in Fe storage (H-Ft and L-Ft), Fe uptake (TfR), and Fe efflux (Fpn). Under conditions of Fe depletion, IRPs can bind to messenger RNAs (mRNAs), decreasing the levels of Ft and Fpn and promoting the translation of TfR *via* the stabilization of its mRNA. Conversely, Fe overload prevents mRNA binding to IRPs, promoting Ft and Fpn translation while reducing TfR levels. The ability of IRP1 and IRP2 to bind mRNAs exerts an important redox control *via* two distinct mechanisms. IRP1 has two conformations: (a) a closed one, triggered *via* an Fe-S cluster that prevents mRNA binding and has aconitase activity; and (b) an open conformation that is favored when $NO^\bullet$, O_2 , and H_2O_2 cause dissociation of the Fe-S cluster. In contrast, the ability of IRP2 to bind mRNAs is controlled by proteasomal degradation, involving the ubiquitin ligase F-box/LRR-repeat protein (FBXL5), which is also an Fe and O_2 sensing protein. FBXL5 has a binuclear nonheme Fe site, and it is stabilized on Fe and O_2 binding, promoting IRP2 degradation. Together, these two mechanisms illustrate the redox control of cellular Fe trafficking (164).

In neurons, Fe uptake is induced by a redox signaling cascade that starts with the activation of the NMDAR (Fig. 4c). Increased intracellular Ca^{2+} induces $NO^\bullet$ production by the neuronal (n) NOS, leading to S-nitrosylation of the small GTPase Dexas1 (Ras-related dexamethasone induced 1), which in turn induces Fe uptake through DMT1 and TfR (51). In hippocampal neurons, NMDAR activation increases intracellular Fe and H_2O_2 production, which activates the redox-sensitive ryanodine receptor (RyR) and promotes Ca^{2+} release from the ER (237) (Fig. 4d). Thus, Fe uptake is clearly part of a redox signaling mechanism that might be important for neuronal plasticity.

Cell death induced by an increase in the labile Fe pool within cells has been defined as a specific entity named ferroptosis. Ferroptotic cell death is a necrotic-like cell death characterized by Fe-dependent lipid peroxidation due to either the formation of $^\bullet OH$ and H_2O_2 *via* Fenton-like reactions

or the activation of lipoxygenases. As such, ferroptosis is counteracted by Fe-chelators and the GSH/GPX4 system. *GPX4* knockout in neurons induces motor neuron degeneration, paralysis (53), and cognitive impairment (121). During ferroptosis, Tf-dependent Fe uptake and release of Fe from lysosomal compartments have been shown to act as important sources for Fe. Interestingly, lysosomal permeabilization is a common phenomenon observed in a number of neurodegenerative disorders, including PD (40, 73). However, during pathological conditions such as neurodegeneration and hemorrhagic stroke, cell death is likely to involve a combination of different pathways and a complex balance between them, including apoptosis, necrosis, autophagic cell death, and ferroptosis as well (77, 143, 357, 398).

During aging, accumulation of Fe in the frontal lobes and striatum is associated with motor dysfunction, loss of myelin sheaths, and memory decline (2, 327). Inflammation, a common hallmark of many brain disorders, increases the expression of DMT1 and hepcidin (354).

Abnormal accumulation of Fe is a common feature of many neurodegenerative diseases, including a group of twelve diseases known as neurodegeneration with brain iron accumulation (NBIA) (225). The most common clinical features of NBIA are movement disorders, such as ataxia, parkinsonism, and dystonia. Although in NBIA Fe is usually accumulated in the globus pallidus, and in some cases in the SN and cerebellum, only two types of NBIA involve the dysfunction of a protein that participates in Fe trafficking: aceruloplasminemia (lack of Cp) and neuroferritinopathy (loss of function mutations in L-Ft) (65, 261, 290, 360). Another neurodegenerative disease associated with disturbed Fe homeostasis is Friederich ataxia, which is linked to mutations in frataxin, an Fe-chaperone involved in Fe-S cluster biogenesis (55).

Altered Fe homeostasis and mitochondrial dysfunction are also hallmarks of PD. While no significant differences in Fe levels have been found in the blood, serum, and CSF (203), Fe is increased in the SN of PD patients (365). Neuromelanin is an Fe-rich pigment found in the dopaminergic neurons targeted in PD (A9) and it has been suggested that its presence makes this neuronal population vulnerable to oxidative damage (91). Decreased levels of serum Cp or its oxidation has also been proposed to exacerbate Fe accumulation in PD (149, 251). DMT1 is found increased in the SN of PD brains (294). Interestingly, Parkin regulates DMT1 expression levels *via* ubiquitination and proteasomal degradation (289).

Fe accumulation in SN might be associated with a dysfunctional delivery of Fe to mitochondria through the “kiss and run” interaction mentioned above (Fig. 4b) (69). Indeed, a Tf/TfR2-dependent mechanism for Fe transport into the mitochondria of dopaminergic neurons has been described (211), while a role for *Tf* and *TfR2* genes in Fe accumulation and mitochondrial dysfunction in PD has been implicated as well (285).

Mitochondrial dysfunction in PD might lead to decreased synthesis of Fe-S clusters, which in turn would activate IRP1 binding to mRNAs, resulting in augmented Fe accumulation (142). Accordingly, knockdown of mitochondrial Grx2 impairs Fe-S cluster biogenesis in dopaminergic cells, decreases the activity of Complex I and aconitase, and increases the activation of IRP1 (171). Loss of PINK1/*PARK6*, another autosomal early-onset PD-related gene, has also been

reported to inactivate Fe-S clusters *via* $O_2^{\bullet-}$ formation. As such, overexpression of FtMt exerts a protective effect on mitochondrial dysfunction and oxidative stress induced by loss of PINK1 (88).

HO-1 protects against neuronal cell death induced by PD-related mitochondrial toxins and α -synuclein, suggesting a role of heme in dopaminergic cell loss. However, HO-1 becomes toxic at high levels, but this effect is counteracted by FtMt (391). Interestingly, the pathogenic PINK1 mutation G309D impairs the induction of HO-1 on oxidative stress (56).

Fe^{2+} can interact with the negatively charged C-terminal region of α -synuclein, accelerating its amyloid aggregation (34). Conversely, α -synuclein overexpression also enables Fe accumulation (254). In PD, oxidative stress has been linked to intracellular Fe levels due to the redox activity of Fe-DA and Fe-neuromelanin complexes (400). Furthermore, overexpression of FtMt protects against neuronal cell death induced by 6-hydroxydopamine (313). Interestingly, a recent report demonstrates that depletion of Fpn has no consequence on the survival of dopaminergic neurons. In contrast, loss of TfR causes Fe deficiency and a PD-like neurodegeneration in mice (212). Previous findings have also suggested a link between Fe deficiency and predisposition to PD, while Fe overload seems to be protective (157, 190, 271). Thus, the exact role of Fe homeostasis in PD is still far from being understood.

A role of Fe in AD has also been proposed based on observations showing that Fe levels are decreased in the serum of AD patients (324), and increased in AD-related brain areas such as the hippocampus, neocortex, and basal ganglia (168). Mitochondrial dysfunction is also observed in AD, which might be related to a disruption in Fe homeostasis. Accordingly, overexpression of FtMt protects against the toxicity of $A\beta$ (380). Fe is accumulated in amyloid plaques in the AD brain (38, 194), consistent with the observation that $A\beta$ is able to bind Fe^{2+} *in vitro* (Fig. 3b) (39). Fe bound to $A\beta$ plaques catalyzes H_2O_2 formation (321).

A novel mechanism for controlling Fe efflux from the BBB was recently discovered, involving the soluble fragment of APP (sAPP), which interacts with Fpn, stabilizing its membrane location (219) and counteracting the effects of hepcidin (216). APP expression is also negatively regulated by IRP1 (57), and production of sAPP and $A\beta$ is increased in AD. Thus, the proposed role of sAPP in Fe movement from BBB into the brain is consistent with the accumulation of Fe in AD brains and the observation of higher levels of $A\beta$ plaques surrounding the brain blood vessels. Indeed, BBB damage is a common feature in AD (217).

Heme metabolism also contributes to AD. APP binds and inhibits HO-1 activity and this effect is enhanced by pathogenic APP mutations (334). In addition, $A\beta$ can form a complex with heme that displays peroxidase activity (16, 112). Conversely, neuroglobin has been proposed to protect against the toxicity of 1–42 $A\beta$ peptides (180). Overall, disruption of Fe homeostasis in AD is likely linked to oxidative stress, and it may also impair NMDAR- and Fe- dependent redox signaling mechanisms (Fig. 4d) impacting neuronal plasticity and memory.

Manganese

Mn is an essential metal required for the activity of a plethora of enzymes, including hydrolases, isomerases, li-

gases, lyases, oxidoreductases, and transferases, involved in diverse metabolic functions such as amino acid (arginase and glutamine synthetase [GS]), lipid, protein, and carbohydrate metabolism (phosphoenolpyruvate decarboxylase), as well as protein glycosylation, energy production, and redox homeostasis (SOD2). The main source for Mn intake is food, but occupational/environmental exposures also occur associated with mining, smelting, welding, alloy, battery, pesticide, and electrical industries. Ingestion and inhalation are the primary routes of Mn exposure. Importantly, inhalation can transfer Mn directly to the brain. The brain is a major target for chronic Mn intoxication (manganism) where Mn is accumulated in nonheme Fe-rich regions. Manganism is defined as a parkinsonism that results in dystonia, hypokinesia, and rigidity as a consequence of impaired neurotransmitter function (133, 352).

Mn can be transported *via* TfR and DMT1 as it competes with Fe for its binding sites (333). Other proposed Mn transporters include the Zn carriers ZIP-8 and ZIP-14, voltage-regulated, store-operated, and ionotropic Glu receptor Ca^{2+} channels, and the Mn-citrate complex shuttle (Fig. 5a) (352). Mn is efficiently detoxified by Fpn at the plasma membrane. In addition, Mn is also detoxified by sequestration in the Golgi *via* the solute carrier family 30 member 10 or human Zn transporter 1 (*SLC30A10/hZnT1*) transporter whose mutations are directly associated with manganism (178). Alternatively, the Ca^{2+}/Mn^{2+} ATPases SPCA1 and SPCA2 also detoxify Mn *via* the secretory pathway (356). Finally, the autosomal recessive early-onset PD-related gene *ATP13A2/PARK9* mediates sequestration of Mn in lysosomes (Fig. 5b) (336). Recently, direct comparison of different detoxification proteins demonstrated that hZnT1 and SPCA1, but not ATP13A2, are involved in Mn detoxification and resistance (246).

Mn^{2+} is the predominant species found in cells that can be oxidized to the more reactive and toxic species Mn^{3+} . Neither Mn^{2+} nor Mn^{3+} can generate free radicals *via* Fenton-type reactions. However, it has been proposed that Mn enhances ROS generation *via* the Mn-catalyzed autooxidation of DA that involves the redox cycling of Mn^{2+} and Mn^{3+} and the generation of ROS and DA-o-quinone (Fig. 5c) (79, 89). Mn accumulates in the mitochondria *via* the mitochondrial Ca^{2+} uniporter (MCU) (111) and increases the accumulation of labile Fe. Both mitochondrial dysfunction and Fe lead to ROS formation and oxidative damage (Fig. 5d) (54, 206). Mn specifically generates H_2O_2 but not $O_2^{\bullet-}$ in the mitochondria *via* complex II (92, 186, 322). Furthermore, Mn impairs oxidative phosphorylation and ATP production.

Astrocytes seem to have a high capacity to accumulate Mn (14). Mn-induced neurotoxicity has been linked to a decrease in Glu uptake by astrocytes (156) leading to excitotoxicity in neurons, as well as the induction of inflammation and increased activity of NOS (Fig. 5e) (95, 185).

Zinc

Zn is a redox-inactive transition metal ion with an oxidation state of +2. The majority of intracellular Zn is bound to proteins and is distributed in the cytoplasm (~50%) and nucleus (~40%) (304) (Supplementary Table S1). The function of Zn as enzyme cofactor is limited to structural roles (*e.g.*, SOD1) (312), or as a Lewis acid that activates

FIG. 5. Mn homeostasis and toxicity. (a) Mn can be transported *via* Tf and DMT1, as well as *via* Zn carriers, ion channels, and shuttle systems. (b) Mn is detoxified by Fpn at the plasma membrane or by its sequestration in the secretory system *via* the ZnT1 transporter or the $\text{Ca}^{2+}/\text{Mn}^{2+}$ ATPases SPCA1/2. ATP13A2 mediates sequestration of Mn in lysosomes. (c) Mn enhances ROS generation *via* Mn-catalyzed autooxidation of DA that involves the redox cycling of Mn^{2+} and Mn^{3+} and the generation of ROS and DA-o-quinones. (d) Mn accumulates in the mitochondria *via* the MCU and increases the accumulation of labile Fe. (e) Mn-induced neurotoxicity is linked to oxidative damage and mitochondrial dysfunction, and also to a decrease in Glu uptake by the EAATs in astrocytes (arrow in EAAT indicates reversal of Glu transport) leading to excitotoxicity in neurons, as well as the induction of inflammation. DA, dopamine; EAAT, excitatory amino acid transporter; Glu, glutamate; MCU, mitochondrial Ca^{2+} uniporter; Mn, manganese; ROS, reactive oxygen species; SPCA, secretory pathway Ca^{2+} ATPase; ZnT, zinc transporter.

substrates for nucleophilic attack (*e.g.*, carbonic anhydrase, where Zn^{2+} catalyzes the hydration of CO_2 to form bicarbonate [HCO_3^-]) (138). Enzymes with Zn-dependent catalytic activity control many cellular processes, including DNA synthesis and brain development. Zn also plays an important role in cell signaling associated with development and learning. In the brain, Zn is highly concentrated in the hippocampus and cortex (304).

The key players in Zn homeostasis are the ZIP transporters that mediate Zn uptake into the cytosol, the zinc transporters (ZnT) that participate in Zn efflux, and MTs involved in Zn chelation. ZIP1 is expressed in astrocytes and microglia (303). In neurons Zn uptake is mediated by, voltage-gated Ca^{2+} channels, ZIP1 and 3 transporters, as well as Ca^{2+} and the Zn^{2+} permeable α -amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor (AMPA) (146, 278, 335). Interestingly, Zn has been reported to be transported into postsynaptic neurons through a complex formed by PrP^C, which is evolutionary linked to ZIP proteins, and the AMPAR (Fig. 6b) (373). ZnT1 is expressed in astrocytes, microglia, and oligodendrocytes, and its expression levels are directly modulated by Zn (247). Hypoxia decreases the levels of ZnT1 in astrocytes inducing the accumulation of cytosolic Zn (257). At the postsynaptic density, the ZnT1 transporter interacts with NMDAR and this complex is regulated during synaptic plasticity (Fig. 6c) (222, 373).

Cytosolic Zn is distributed to different organelles, including synaptic vesicles, Golgi, ER, and mitochondria. Similarly, Zn uptake by these organelles is performed by ZnTs, while ZIPs participate in Zn efflux into the cytosol (155). Zn

modulates cellular signaling pathways and acts as a neuro-modulator. ZnT3 participates in the transport and accumulation of Zn within synaptic vesicles of glutamatergic terminals (Fig. 6a) (125). During synaptic transmission, Zn is released with Glu, where it inhibits the activity of NMDAR and AMPAR (9, 154), modulating neuronal excitability and long-term synaptic plasticity (long-term potentiation [LTP] and long-term depression). In addition, Zn regulates the activation of the tropomyosin kinase receptor B (TrkB) (304). A metabotropic Zn-sensing receptor (mZnR) has also been reported (31). At the synapse, Zn can also bind to MTs, A β , and PrP^C (Figs. 3c and 6).

Although Zn^{2+} is a nonredox-active metal ion, it participates in redox signaling through several mechanisms. MTs bind about a fifth of the intracellular Zn with a stoichiometry of 1:7. MTs and proteins containing Zn-finger domains use Cys residues to bind to Zn^{2+} ions. Zn coordination stabilizes the reduced state of Cys thiol groups preventing their oxidation and subsequent formation of disulfide bonds. Transcription of MTs is induced by oxidative stress *via* Nrf2, and by heavy metal exposure *via* metal-response elements (MREs). MREs are recognized by the Zn-finger domain containing protein metal-responsive transcription factor-1 (MTF1, also known as MRE-binding transcription factor-1 or metal regulatory transcription factor-1). MTF1 senses Zn levels. Furthermore, *via* Zn displacement from MTs or Cys oxidation, MTF1 also senses heavy metal toxicity (Cd) and oxidative stress. In addition to MTs, MTF1 regulates the transcription of a number of genes involved in redox homeostasis and metal ion detoxification, including Zn transporters,

FIG. 6. Zn trafficking at the synapse. (a) Zn ions are loaded into neurotransmitter vesicles by ZnT3, and are coreleased with Glu during synaptic transmission. In the synaptic cleft, Zn can bind to MT, A β , PrP^C, and NMDAR. (b) Recently, two links between synaptic activity and Zn transport have been discovered: Zn uptake by the postsynaptic terminal occurs via a complex formed by PrP^C and AMPAR, (c) while ZnT1 interacts with NMDAR and modulates spine morphology. AMPAR, α -amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor.

Fr, Fpn, ATP7(A/B), Trx, selenoproteins, and γ -glutamylcysteine ligase (GCL), a rate-limiting enzyme in GSH synthesis (119). The role of MTF1 in brain function and redox homeostasis is unclear. MTF1 has been shown to regulate the expression of β -synuclein (220), which is thought to act as a negative regulator of its homologue α -synuclein (126). Interestingly, deletion of *MTF1* induces lethality in Parkin-deficient flies (*Drosophila melanogaster*) (293).

Altered Zn levels have been reported to promote neuronal injury. Upon Cys oxidation, Zn is released from MTs (255). Cellular acidification also releases intracellular Zn in neurons (159). In a recent report, AMPA-induced oligodendrocyte cell death was shown to be linked to Zn mobilization from mitochondria and protein-bound pools that were mediated by cytosolic acidification, independently from ROS (213). Exposure of mitochondria to Zn promotes increased ROS formation (305). While no specific mitochondrial Zn transporter(s) has been identified, potential candidates include the MCU, ZIP8, and Znt2 transporters (30, 199, 307). Zn also increases NOX-derived ROS formation and NOS activity (162). High extracellular Zn enhances microglia activation and ROS formation (130). Zn deficiency also induces oxidative stress via a reduction in the activity of SOD1 (378), and an impairment in the transcriptional regulation of GCL by Nrf2 (253).

Alterations in Zn homeostasis are associated to neurodegenerative diseases. Serum levels of Zn are decreased in AD patients (358), while Zn is enriched in A β plaques (364). Furthermore, a decrease in the levels of Znt3 and MT-III (390) is found in AD. Importantly, the predominant localization of A β plaques in Zn-containing glutamatergic synapses might explain why they are primarily found in the neocortex (304). Zn promotes a rapid, but reversible, aggregation of A β that is different to the aggregation of A β or A β -Cu complexes (25). Zn also reduces the toxicity of Cu-induced A β aggregates (214). *ZnT3* knockout increases

soluble A β in transgenic APP mice corroborating the role of extracellular Zn in plaque formation (172).

Elevated Zn levels have been found in the SN of PD brains (74), while reduced levels of Zn in serum and plasma have been linked to an increased risk for PD (80). Zn has been shown to potentiate the toxicity of DA as well (189). Furthermore, Zn chelation reduces the toxicity of mitochondrial PD-related toxins (310). Recently, ATP13A2 was identified as a Zn transporter localized to multivesicular bodies. Loss of function mutations of *ATP13A2* induces alterations in Zn homeostasis and mitochondrial dysfunction (259).

Xenobiotic Metals

Measurable concentrations of xenobiotic metals with no physiological functions are present in humans (Supplementary Table S1) (103). In addition, environmental or occupational exposures to xenobiotic metals may take place by inhalation, ingestion, or skin penetration and are often linked to the development of toxicity and pathological conditions (Supplementary Table S1). Metals can reach the CNS from the vascular lumen affecting neuronal and glial function. Metals hijack transport systems of essential metals to pass through the BBB and enter neuronal tissues (molecular mimicry). Metal toxicity is largely attributable to their physicochemical properties, which mediate their interference with cellular biochemical systems, including redox-related processes (205, 355).

Environmental or occupational exposure to xenobiotic metals has been reported to contribute to neuronal dysfunction (cognitive, motor, and behavioral) and in some cases, neurodegeneration. However, the mechanisms involved are largely unclear. We next review the sources and routes of exposure to xenobiotic metals; the metabolic pathways involved in their transport and activation, and the mechanisms by which they alter cellular redox balance to promote neurotoxicity.

Arsenic

As is naturally present in air, water, and soil and is the 20th most abundant element in the earth's crust and 12th in the human body. This metal is named inorganic As (iAs) when found combined with other elements such as O₂, chlorine (Cl), and sulfur (S). Combined with carbon (C) and hydrogen (H) is referred to as organic As. In the environment and within the human body, iAs predominantly exists in two oxidation states: arsenite +3 (or AsIII, found as arsenic trioxide [As₂O₃], sodium arsenite [NaAsO₂], and arsenic trichloride [AsCl₃]), and arsenate +5 (or AsV found as arsenic pentoxide [As₂O₅], arsenic acid [H₃AsO₄], and arsenates [PbHAsO₄, Ca₃(AsO₄)₂]).

iAs has been widely used as a therapeutic agent to treat leukemia. Currently, iAs compounds are predominantly used in pesticides, herbicides, cotton desiccants, wood preservatives, alloys for batteries, and in semiconductors and light-emitting diodes. Millions of individuals are currently exposed to iAs across the world due to natural groundwater contamination. Fish and crustaceans contain very high levels of organic arsenobetaine but no toxicity has been reported *in vivo* (382). The concentration of iAs in natural surface and groundwater is generally about 1 parts per billion (ppb) of water but it may exceed 1000 ppb in contaminated areas or where iAs soil levels are high (118, 200) (Supplementary Table S1).

While As is considered a carcinogen, in the brain, acute exposure to iAs can induce encephalopathy, with symptoms such as confusion, hallucinations, reduced memory, and emotional lability (exaggerated changes in mood or affect). Long-term exposure to lower levels of iAs can lead to the development of peripheral neuropathies.

There are reports of neurobehavioral alterations (cognitive function, verbal abilities, long-term memory, and motor skills) in children exposed to As concentrations ranging from 5 to 50 ppb in water, in Bangladesh (260), Mexico (45, 287), and in the United States (370). Although scientific understanding of the developmental neurotoxicity of As is still evolving, epidemiological and toxicological studies clearly show that As is a developmental neurotoxicant that affects intellectual function. Moreover, exposures even below current safety guidelines are associated with decrements in full-scale intelligence quotient (IQ) and memory (90, 347). Evidence in experimental models, including mice, rats, *Caenorhabditis elegans* (worm), and *Danio rerio* (zebrafish), has replicated many of the observations in humans supporting the notion that As can lead to cognitive, locomotor, and neurological impairment (85). Gestational exposure to NaAsO₂ leads to a significant iAs accumulation in the mice offspring's brain (280). As neurotoxicity has been linked to changes in neurotransmitter metabolism and synaptic transmission (85, 276, 280). However, the mechanisms involved remain unclear.

In the environment, oxygenated water contains iAsV species, while in reducing environments iAsIII species are prevalent. iAsV enters cells through phosphate transporters to be subsequently reduced to iAsIII, while iAsIII is transported *via* aqua(glycerol)porins (AQP), organic anion transporters, and glucose transporters (GLUT) (Fig. 7a) (44, 187, 348). Once in the cytoplasm, iAsIII is methylated by different mechanisms. Oxidative methylation (Fig. 7b) is

mediated by arsenite methyltransferase (AS3MT) that uses S-adenosylmethionine (AdoMet) as a cosubstrate. AS3MT methylates iAsIII to monomethylarsonic acid or arsonate (MMAV) that is reduced to monomethylarsonous acid (MMAIII) before being methylated again to dimethylarsinic acid (DMAV) by AS3MT (353, 372). Finally, DMAV is reduced generating dimethylarsinous acid (DMAIII). The reduction of pentavalent arsenicals (iAsV, MMAV, and DMAV) in this pathway is now well recognized to be mediated by the Trx/TR system, but GSH seems to increase the methylation rates by an unknown mechanism (76).

Developmental exposure to As alters the methylation patterns of genes involved in neuroplasticity likely due to changes in AdoMet, but its long-term implications are unclear (207). Recent *in vivo* studies demonstrated that the alterations in synaptic plasticity (LTP), memory, and learning induced by gestational exposure to iAs were associated with an increase in extracellular Glu levels and downregulation of AMPAR subunits (244).

As methylation *via* the GSH conjugation mechanism is based on the formation of GSH complexes with iAsIII resulting in arsenic triglutathione [As(SG)₃] (Fig. 7c). Conjugation of iAsIII with GSH has been proposed to occur nonenzymatically, but enzymatically as well by the activity of glutathione-S transferases (GST isoforms GSTO1, GSTM1, or GSTP1) (173, 372). As(GS)₃ is subsequently methylated by AS3MT to form monomethylarsinic diglutathione [MMA(GS)₂] and then again to generate dimethylarsinic GSH [DMA(GS)]. At low GSH levels, As(GS) conjugates are hydrolyzed and then oxidized to generate MMAV and DMAV (372). A third mechanism for iAsIII methylation has been recently proposed, where instead of As(GS) conjugate formation, iAsIII binds to protein-Cys (thiol) and is methylated while still being conjugated to proteins (Fig. 7d). This hypothesis is supported by the preferential binding of iAsIII to protein-Cys when compared to GSH (284).

Methylated (and maybe unmethylated) As metabolites are exported through the multidrug resistance proteins (MRP1, MRP2, or MRP4) (173, 317, 388) (Fig. 7e). AS3MT is ubiquitously expressed in all brain regions, and animal studies have shown that the iAs that crosses the BBB is methylated and accumulated across the brain, with the highest accumulation observed in the pituitary gland (297). Interestingly, knockout mouse for P-glycoprotein accumulates more As in the brain (183). Endothelial cells and astrocytes feet surrounding capillaries are the first barrier of detoxification of xenobiotics entering from the circulation. We (unpublished data) and others have observed that the resistance of astrocytes to iAsIII is mediated by MRPs (332).

iAs generates ROS and dimethylarsenic or peroxy radicals that in turn lead to lipid peroxidation and the accumulation of oxidized by-products (MDA and HNE) (Fig. 7f). Importantly, MMAIII and DMAIII are proposed to be more potent toxicants than iAsIII due to their increased ability to generate radicals (392). Oxidative stress has been reported in brain regions of different animal models and in neurons and glial cell cultures exposed to As compounds (48, 107, 108, 243, 394).

Mitochondria have been proposed to be a primary source for ROS formation by iAs (Fig. 7g) (97, 150). Chronic iAs exposure generates mitochondrial oxidative stress in the rat brain by impairment of mitochondrial complexes I, II, and IV

FIG. 7. iAs biochemistry, redox signaling, and neurotoxicity. (a) iAsIII species prevail in anaerobic conditions, while aerobic environments contain iAsV species. iAsIII enters cells through AQP9/7 and GLUT, while iAsV uses phosphate transporters. Three mechanisms for iAs methylation have been proposed. (b) Oxidative methylation refers to the progressive reduction of AsV to AsIII metabolites by the Trx/TR system and the oxidative methylation of AsIII species by AS3MT. (c) The GSH conjugation pathway is based on the formation of As(GS)₃ by the GSTs. As(GS)₃ is subsequently methylated by AS3MT. (d) The protein thiol conjugation mechanism suggests that instead of As(GS)₃, iAsIII binds to protein thiols and is methylated while still being conjugated to proteins. iAsIII methylation is likely to alter epigenetic signatures by alterations in AdoMet, a cosubstrate required for methyl group transfer. (e) Methylated metabolites and GSH/protein complexes are highly reactive and are exported through the MRPs. (f) DMA(GS) can form DMAH and react with O₂ to form DMAH• and DMAOO•. DMAIII also reacts with O₂ and forms DMAOOH. These reactive species lead to lipid peroxidation and protein carbonylation (oxidative stress). (g) AsV can replace phosphate in several metabolic pathways (arsenylation) where the end product is reduced AsIII. AsV binds ADP *via* ATP-synthase and uncouples oxidative phosphorylation and ATP formation in the mitochondria. AsV is also arsenylated by GAPDH to generate iAsV-3-P-glycerate from G3P. (h) iAsIII toxicity generates ER stress likely *via* thiol depletion and alterations in redox balance. (i) AsIII binds to thiol containing molecules (coenzyme A, DLA, GSH) and protein thiols inactivating enzymatic function. (j) iAsIII toxicity is counteracted by Nrf2 and MTF1 that mediate the transcriptional-dependent induction of antioxidant systems and MTs. AdoMet, S-adenosylmethionine; AQP, aqua(glycerol)porin; AS3MT, arsenite methyltransferase; AsIII, arsenite +3; As(SG)₃, arsenic triglutathione; AsV, arsenate +5; DLA, dihydroliipoamide; DMA(GS), dimethylarsenic GSH; DMAH, dimethylarsine; DMAH•, DMAH radical; DMAIII, dimethylarsinous acid; DMAOO•, dimethylarsine peroxy radical; DMAOOH, dimethylated arsenic peroxide; G3P, glyceraldehyde 3-phosphate; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GLUT, glucose transporters; GSTs, glutathione-S transferases; iAs, inorganic As; iAsV-3-P-glycerate, 1-arsenato-3-phospho-D-glycerate; MRPs, multidrug resistance proteins; MTF1, metal-responsive transcription factor-1; Nrf2, nuclear factor erythroid-2-related factor 2; O₂, molecular oxygen; Trx, thioredoxin.

activities followed by increased ROS generation, lipid peroxidation, and protein carbonylation (275). Mitochondrial pyruvate dehydrogenase is also directly inhibited by iAs (136). In addition, iAs reduces the levels of peroxisome proliferator-activated receptor gamma coactivator 1- α (PGC-1 α), downstream targets Nrf1 and Nrf2, and the mitochondrial transcription factor A (TFAM) decreasing mitochondrial biogenesis (274). ER stress has also been shown to contribute to iAs toxicity, but the mechanisms involved remain unclear (Fig. 7h) (182).

iAs toxicity has also been attributed to the ability of AsV to replace phosphate in several metabolic pathways (arsenylation) where the end product is the reduction of AsV to AsIII, because the arsenylated by-product is more readily reduced than AsV itself (Fig. 7g). AsV uncouples oxidative phosphorylation and ATP formation in the mitochondria by binding to ADP *via* ATP synthase. Replacement of phosphate in glycolysis also impairs carbon flux and ATP production. Reaction of AsV with glucose generates glucose 6-arsenate, an analog of glucose 6-phosphate that is suggested to act as an inhibitor of hexokinase. AsV is also arsenylated by glyceraldehyde 3-phosphate dehydrogenase (GAPDH) to produce the unstable product 1-arsenato-3-phospho-D-glycerate (iAsV-3-P-glycerate). Purine nucleoside phosphorylase, glycogen phosphorylase, and mitochondrial ornithine carbamoyl transferase (OCT) have also been shown to arsenylate AsV (139, 245, 340). Thus, energy failure, alterations in central carbon metabolism, and mitochondrial dysfunction are consequences of AsV toxicity.

AsIII binds to thiol containing molecules (coenzyme A, GSH, and dihydrolipoamide also known as dihydrolipoic acid [DLA]) and protein-Cys thiols inactivating enzyme function (Fig. 7d, i). AsIII has higher affinity for dithiols than monothiols as demonstrated by the transfer of AsIII from the GSH-adduct to 2,3-dimercaptosuccinic acid (DMSA) a sulfhydryl-containing metal chelator used to treat heavy metal toxicity. In addition, AsIII conjugated with GSH has the ability to bind protein thiols, which highlights the importance of detoxification of GSH-As adducts from the cell (230). Dithiol molecules such as the cofactor DLA and dithiol oxidoreductases Trxs, Trx reductase (TrxR), Prxs (except for monothiol Prx6), Grx, and GR, as well as proteins with adjacent Cys (MT), have been reported to avidly bind AsIII (Fig. 7d, j) (50, 279, 311, 393, 397). In addition to binding AsIII, Zn finger domains have been shown to be oxidized upon As binding (396). Binding of AsIII to DLA (Fig. 7i) is expected to interfere with the TCA cycle and energy production as DLA is a cofactor for the pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase complexes that catalyze the synthesis of acetyl-CoA and succinyl-CoA, respectively. DLA reverses protein oxidation and loss of protein-SHs in the brains of rats exposed to high levels of iAs (82, 296, 315, 316).

As activates the cystine/Glu exchanger system (xCT) in microglia to increase extracellular Glu levels (320), while in astrocytes it decreases the expression levels and activity of GS and Glu transporters (GLAST/excitatory amino acid transporter (EAAT) 1 and GLT-1/EAAT2) (48, 395). Importantly, these effects were linked to an increase in GSH levels and Nrf2 activity (Fig. 7i), but not oxidative stress (48). Accordingly, activation of Nrf2 by As seems to involve a noncanonical pathway where inhibition of autophagy

leads to the accumulation of the ubiquitin-binding protein/adaptor p62 that sequesters Keap1 (169). iAsIII toxicity is also counteracted by the transcriptional regulation of MT *via* MTF1 (Fig. 7j) (129).

Lead

Inorganic Pb remains one of the most studied toxic elements due to several reasons. To begin with, human contact with Pb started very early in human civilization, and its toxic effects were also known since then. However, more importantly, Pb is neurotoxic leading to lower IQ even at lower doses than those recommended by the World Health Organization (10 ppb in drinking water). Human exposure to Pb not only occurs occupationally but also environmentally. The presence of Pb in the environment has multiple sources such as gasoline, industrial processes, paint, water pipes, and solder in canned food. It is present in air, household dust, soil, water, and food (Supplementary Table S1). Environmental Pb levels have fortunately decreased, especially in those countries where the Pb addition to gasoline and paints was banned. This prohibition was enforced after several studies associated the presence of high blood levels of Pb with impaired or diminished cognitive functions. Epidemiological studies have clearly shown that exposure to Pb in early stages of development is associated with significant deficits in neurobehavioral performance, including lower IQ, attention deficits, and aggressiveness later in life. Despite all the enforced restrictions, Pb contamination is still a major public health concern. For example, in November 2000 in Washington DC, there was a "lead drinking water crisis" triggered by a change in the disinfectant used to clean the water, this contamination affected hundreds of kids for 3 years. The health consequences of the recent crisis of Pb-contaminated water in Flint Michigan (United States, 2015) are still to be revealed in the future (68, 84, 124, 298).

Inhalation and ingestion of Pb and Pb-containing particles or products are the main routes of Pb entry into the body. Young children are especially vulnerable because they show higher gastrointestinal absorption than adults. Inhaled Pb particles are quickly absorbed in alveoli and distributed to other organs through the circulation. Thus, blood lead levels (BLL) are reliable biomarkers of exposure and risk. However, BLL do not reflect the total Pb body burden because Pb is absorbed in bones where it can be stored for several years (68). Currently, the acceptable BLL for children is lower than 10 $\mu\text{g}/\text{dl}$ (0.48 μM) (49, 376), but due to the devastating effects that might occur later in life, there is a consensus to recommend efficient surveillance methods for children protection to reduce BLL to the lowest possible level (141). Pb binds with high affinity to erythrocytes' δ -aminolevulinic acid dehydratase (ALAD) that catalyzes the second step in the porphyrin and heme biosynthetic pathway, causing the accumulation of aminolevulinic acid (ALA) in both plasma and urine, which is used as a biomarker of exposure (248).

Pb can cross the BBB and cell membrane because of its ability to mimic Ca^{2+} and Fe^{2+} ions (Fig. 8a) (205, 298). In children, due to a more permeable BBB and a lower bone storage capacity for Pb, the amount of Pb passing into the nervous system is higher than in adults. The highest accumulation of Pb has been reported in the hippocampus, amygdala (116), and choroids plexus (201). The PNS may

FIG. 8. Pb neurotoxicity and synaptic signaling. (a) Pb enters cells due to its ability to mimic Ca^{2+} and Fe^{2+} ions. (b) Inside the cell, Pb can trigger oxidative stress by different mechanisms, including the accumulation of ALA; the formation of $\text{Pb}^{2+}\text{-O}_2^{\bullet-}$ complexes; and the release of labile Fe^{2+} from Ft. (c) Pb can also form complexes with GSH [$\text{Pb}(\text{GSH}_{2-3})$] and bind to protein thiols. (d) Mitochondrial dysfunction and oxidative stress induced by Pb have also been linked to MCU. (e) Pb can displace Zn^{2+} and impair Zn^{2+} binding protein function. Furthermore, Pb interferes with the Se-dependent redox processes. (f) Finally, Pb can prevent CaM activation and thus reduce NOS activity. ALA, aminolevulinic acid; CaM, Ca^{2+} /calmodulin; NOS, nitric oxide synthase; $\text{O}_2^{\bullet-}$, superoxide anion radical; Pb, lead; Se, selenium.

accumulate considerably more Pb than the CNS. Animals chronically exposed to Pb had impaired dendritic spines and synapse formation (306). Developmental exposure to Pb impacts the prefrontal cerebral cortex, hippocampus, and cerebellum regions, which can lead to neurological disorders, mental retardation, behavioral problems, and nerve damage (242). Early life exposure to Pb has also been linked to neurodegenerative diseases such as AD and PD (62, 209).

The mechanisms of Pb toxicity include the ability of Pb to bind SH groups of proteins Cys and to mimic or compete with Ca^{2+} , Fe^{2+} , and Zn^{2+} (Fig. 8b, c, e, f) (99, 283). Zn deficiency increases the toxicity of Pb (4). The generation of oxidative damage by Pb *in vitro* and *in vivo* suggests that ROS also participate in Pb toxicity. For example, Pb acetate induces the opening of the mitochondrial permeability transition pore in human neuroblastoma SH-SY5Y cells *via* ROS (384). Pb can form a $\text{Pb}^{2+}\text{-O}_2^{\bullet-}$ complex with higher oxidizing capacity than $\text{O}_2^{\bullet-}$ (3). In addition, accumulated δ -ALA by Pb-induced ALAD inhibition can be subsequently oxidized to generate $\text{O}_2^{\bullet-}$, $\bullet\text{OH}$, and H_2O_2 . Pb *per se* has been reported to stimulate Fe^{2+} -initiated lipid peroxidation (Fig. 8b) (337). Early postnatal exposure of rats to Pb leads to a higher accumulation of oxidative DNA damage in the cerebral cortical tissue when compared with aged controls or aged mice exposed acutely to Pb (36).

Perinatal exposure to Pb acetate inhibits the activity of brain acid and alkaline phosphatases, catalase, acetylcholinesterase, and ATPases (12). Similar observations have been made for the activities/levels of SOD1, GPX1, and GPX4 in the hippocampus, and for mitochondrial SOD2 and GSH,

both in the cortex and hippocampus (19). Antioxidant nutrients such as vitamin E, vitamin C, vitamin B6, β -carotene, and DLA, as well as metal chelators such as DMSA, or replenishment of displaced metals has been shown to be beneficial against Pb-induced oxidative stress in the brain (98, 236, 256, 258, 277, 367). Diet supplementation with Zn and Se, which participates in the regulation of the GSH and Trx antioxidant systems, can effectively outcompete Pb binding to Zn- and Se-binding sites (Fig. 8e) (135).

Pb interferes with and disrupts Ca^{2+} signaling and homeostasis leading to excitotoxicity. In addition, Glu potentiates Pb-induced cell death in PC12 cells (267). Recently, oxidative stress induced by Pb has been shown to be linked to changes in the levels of MCU (Fig. 8d) (383). Other important intracellular targets of Pb in the brain are both neural NOS and endothelial NOS due to an impairment in their Ca^{2+} /calmodulin (CaM)-dependent activation (Fig. 8f) (241). Importantly, Pb amplifies Glu-induced oxidative stress in a Ca^{2+} -independent manner, but neither Ca^{2+} nor ROS seem to be essential for the enhanced cytotoxicity of combined exposure to Glu and Pb (191, 238).

Mercury

Hg is a transition metal that exists as elemental, inorganic, and organic Hg (Fig. 9a). Hg is ubiquitously found in the environment as sulfide compounds generated from volcanic activity and erosion, or released by anthropogenic sources such as fuel combustion, waste disposal, and industrial activities (Supplementary Table S1). Elemental or metallic Hg

FIG. 9. Hg redox-related toxicity mechanisms in brain cells. (a) Hg species are highly transformed (oxidation or methylation) before they are absorbed into organisms. MeHg and EtHg form a complex with Cys (CH_3HgCys) and are transported across the membranes *via* LAT. (b) MeHg suffers dealkylation and thiol exchange to form Hg^{2+} . (c) Thiol exchange reactions of CH_3HgCys complexes with low-molecular-weight thiols (GSH) and protein thiols alter the cellular redox balance. MeHg also has a strong affinity for selenol groups. (d) GSH-MeHg adduct formation (CH_3HgGS) is catalyzed by the GSTs and adducts are detoxified by MRPs. (e) MeHg also induces mitochondrial ROS and energy failure. Furthermore, MeHg-induced neurotoxicity has been ascribed to a reduction in Glu uptake by astrocytes *via* EAAT triggering neuronal excitotoxicity (arrow in EAAT indicates reversal of Glu transport). Cys, cysteine; Hg, mercury; EtHg, ethylmercury; Hg^{1+} , inorganic mercurous ions; Hg^{2+} , inorganic mercuric ions; LAT, L-type neutral amino acid transporter; MeHg, methylmercury.

(Hg^0) used in thermometers and amalgams is primarily absorbed *via* inhalation, while inorganic mercury (Hg^{1+} or $^{2+}$) used in medicine and everyday life products is partially absorbed through the gut. Organic Hg (ethylmercury [EtHg or $\text{C}_2\text{H}_5\text{Hg}$] and methylmercury [MeHg or CH_3Hg]) is originated from atmospheric sources that are deposited in water body surfaces to be biomethylated and magnified in the food chain (Fig. 9a). Around 95% of MeHg is absorbed by the gastrointestinal tract making it the most toxic Hg species. Neurotoxic signs of Hg intoxication are vast and include ataxia, dizziness, insomnia, speech impairment, arthralgia, cognitive and behavioral changes, seizures, fatigue, and sensory disruption. While there has been an association between Hg exposure and neurodegeneration or autism, the neurological effects of chronic exposure to Hg are largely unclear. However, research has clearly demonstrated that Hg impairs neuronal development, communication, and myelination (89).

Most of the studies regarding the mechanisms involved in Hg neurotoxicity have been done using MeHg. MeHg and EtHg are potent electrophiles that form a complex with Cys (CH_3HgCys or $\text{C}_2\text{H}_5\text{HgCys}$), and then transported across the BBB and into neuronal cells *via* L-type neutral amino acid transporters (LAT1 and 2) (Fig. 9a) (318, 385, 399).

A high percentage of Hg in individuals intoxicated with MeHg is found as Hg^{2+} , suggesting that dealkylation of MeHg is an important mechanism for the high persistence of Hg in the brain (Fig. 9b) (72). Thiol exchange from CH_3HgCys to low-molecular-weight thiols (GSH) and protein thiols has been proposed to be central mechanisms by which MeHg induces GSH depletion, inhibition of thiol-dependent antioxidant systems, and alters the activity or

function of proteins with redox-sensitive Cys (signaling proteins, metabolic enzymes, neurotransmitter receptors, and transporters) (Fig. 9c) (89). MeHg also has a stronger affinity for selenol groups (selenohydryl groups in selenocysteines) compared with thiol groups. As such, selenoproteins are important targets for direct electrophilic attack of MeHg or transfer from thiol adducts (CH_3HgCys , CH_3HgGS , or CH_3HgPS [protein-Cys adduct]) (Fig. 9c) (104, 221). GSTs have been proposed to mediate the formation of CH_3HgGS adducts, which are detoxified by MRP1-mediated transport (Fig. 9d). GSH synthesis, GST, and MRP1 levels are regulated transcriptionally by the Nrf2 antioxidant system (152, 292, 349).

MeHg induces mitochondrial ROS and energy failure (175, 233). Neurotoxicity induced by MeHg has also been ascribed to its inhibitory effect on Glu uptake by astrocytes, triggering neuronal excitotoxicity (15, 235) (Fig. 9e).

Hg^0 absorbed through the respiratory tract is oxidized to inorganic mercurous (Hg^{1+}) and mercuric ions (Hg^{2+}) (Fig. 9a). While inorganic Hg ions have limited access to the CNS, they induce profound neurotoxic alterations that seem to be mediated as well by their binding to thiol groups (89). Accordingly, MTs exert protective effects against Hg^0 -induced neurotoxicity (387) (Fig. 9b).

Other xenobiotic metals

Aluminum. Al is one of the most abundant metals in the earth's crust (8.1%). Al has a plethora of uses in industry and manufacturing, as well as in food additives. As such, human exposure is primarily originated from food and drinking water. Importantly, pharmaceuticals have higher levels of Al

FIG. 10. Mechanisms of Al and Cd neurotoxicity. (a) Al is bound to Tf, which mediates its transport across the BBB *via* the Tfr, but a Tf-independent Al transport also exists. (b) Al promotes A β aggregation and (c) mitochondrial dysfunction triggering neuroinflammation and NO $\bullet$ formation. (d) Al $^{3+}$ has been proposed to react with H $_2$ O $_2$ to produce AlO $_2^{\bullet-}$ that can promote oxidative damage. (e) Al toxicity is also related to its ability to displace other metals (Ca or Fe). (f) Cd transport across membranes is through molecular mimicry *via* several transporters such as Cu/Zn transporters, DMT1, and Ca $^{2+}$ -channels. (g) High concentrations of Cd can block Ca $^{2+}$ currents as well. (h) Cd toxicity is linked to its ability to bind thiol containing molecules such as GSH, and protein-Cys (Trx and MT), as well as the displacement of redox-active metals such as Fe. Cd detoxification of cells is facilitated by the activity of GST and the detoxification of GSH-Cd adducts *via* MRPs. Al, aluminum; AlO $_2^{\bullet-}$, aluminum superoxide radicals; Ca, calcium; Cd, cadmium.

compared to food. Occupational exposures to Al are related to mining, processing, and welding (359) (Supplementary Table S1). While Al is poorly absorbed in the gut, inhalation mediates direct transfer to the brain *via* the olfactory system (341). Importantly, $\sim 85\%$ of Al in blood is bound to Tf, which is considered to mediate its transport across the BBB (Fig. 10a) (288), but Tf-independent Al transport also exists. Interestingly, monocarboxylate and xCT transporters have also been proposed to mediate the transport of Al-citrate complexes (240, 386). Acute Al toxicity occurs as a result of occupational exposure or chronic renal failure and is known to target the nervous system. Al is neurotoxic in animal models triggering the accumulation of neurofibrillary tangles and impairment of cognitive, behavioral, and motor functions. Al promotes A β aggregation, mitochondrial dysfunction, and triggers neuroinflammation (Fig. 10b, c) (24, 202, 309). However, conflicting results exist regarding the association of Al with any human disease, including AD (37, 359, 377).

Al exists primarily in a trivalent state (Al $^{3+}$). While Al has no redox capacity, Al toxicity is linked to oxidative damage. Al $^{3+}$ has been proposed to react with H $_2$ O $_2$ to produce Al superoxide radicals (AlO $_2^{\bullet-}$) that can deplete mitochondrial Fe and promote generation of ROS (Fig. 10d) (166). However, because of its high reactivity, Al is primarily found forming insoluble oxides whose toxicity seem to be related with the displacement of other biological cations (Ca $^{2+}$, Fe $^{2+}$, or Mg $^{2+}$) (Fig. 10e) (377).

Cadmium. Cd is a transition metal whose use in industry has increased dramatically in the recent years. Cd is widely used in batteries, alloys, and pigments, and produced as a by-

product from the extraction of other metals from ores. Food is the major source for Cd exposure as both animals and plants accumulate high levels of Cd. Inhalation is the prevalent route of Cd exposure due to industrial emissions and occupational activities (tobacco) (Supplementary Table S1). Cd neurotoxicity seems to occur only during development, before complete BBB formation, or in association with BBB dysfunction. Cd transport across membranes is thought to be mediated by molecular mimicry *via* several transporters and receptors for essential metals such as Cu/Zn transporters, DMT1, and Ca $^{2+}$ -channels (Fig. 10f) (117, 131, 174, 224, 339). Importantly, at high concentrations, Cd also has the ability to block Ca $^{2+}$ currents (Fig. 10g).

Cd toxicity is linked to its ability to bind thiol containing molecules such as GSH, and protein-Cys (Trxs and MT) and as a consequence, displacement of redox-active metals and mitochondrial and metabolic dysfunction (Fig. 10h) (363). Cd detoxification of cells is facilitated by the activity of GST and the detoxification of GSH-Cd adducts *via* MRPs (Fig. 10h) (181, 339). Accordingly, resistance to Cd-toxicity is directly associated with the Nrf2-mediated antioxidant response (366).

Conclusions and Perspectives

Metals are important for brain function and human health. Thus, alterations in their content and/or distribution are expected to exert neurotoxicity. Both alterations in the homeostasis of essential metals and environmental exposure to xenobiotic metals can have silent chronic effects leading to neurodegeneration and neurological dysfunction (behavioral and cognitive alterations). The neurotoxic mechanisms by

which metals impact neuronal or glial function are starting to become elucidated.

In this review, we have summarized how essential metals are trafficked in the brain. It is interesting to note that the mechanisms involved in metal transport and homeostasis are strongly linked to the chemical properties of each metal ion, while their coordination chemistry preferences also allow them to share some metal transport routes. For instance, Cu and Fe go through several redox cycles during their transport, while Mn and Zn remain in the same oxidation state. Metal trafficking in the cell is tightly regulated to control the high reactivity toward O_2 of some metal ions, such as Fe^{2+} and Cu^+ , or to keep in solution otherwise insoluble species such as Cu^+ and Fe^{3+} . Moreover, while similar O-based ligand coordination preferences of Mn^{2+} , Fe^{2+} , and Fe^{3+} allow them to share some transport systems, the affinity of Zn^{2+} and Cu^+ for Cys ligands makes MTs important players in their homeostasis. In fact, a close relationship between cellular redox environment and metal transport has been recently demonstrated for Cu and Fe (Figs. 1D and 4C).

Since metal trafficking machineries in neurons and astrocytes resemble those of other extensively studied mammalian cells, our understanding of intracellular metal homeostasis has advanced significantly. In contrast, metal trafficking at the synapse and the role in neuromodulation have just begun to be revealed, and point to a close inter-relationship among Zn, Cu, and Fe. For example, the synaptic release of Zn and Glu ultimately leads to the activation of NMDAR and the activation of signaling pathways that lead to postsynaptic Cu release and Fe uptake. Clearly, the close interplay between these metals at the synapse must play an important role in neuromodulation, while disturbed metal trafficking in neurodegenerative diseases would impact these processes.

We have also illustrated the differential alteration of metal homeostasis that occurs in neurodegenerative disorders as well as the key metal-protein interactions that might be involved in protein aggregation and metal-mediated oxidative damage. Understanding these interactions at the molecular level will shed light into the role of essential metals in neurodegenerative diseases.

Metals are transported across the BBB and into brain cells by selective transport systems for essential metals, while xenobiotic metals hijack those transporters *via* molecular mimicry (Supplementary Fig. S1a). The ability of xenobiotic metals to be transported and/or react with cellular targets is strongly determined by their metabolism *via* reduction/oxidation reactions, methylation, or adduct formation ($Mt0 \rightarrow Mt1 \rightarrow Mt2$). Phase II enzyme systems, GSH/GST, and MTs are essential for the detoxification of metals (Supplementary Fig. S1b). Metals induce or enhance ROS and RNS formation leading to oxidative stress (Supplementary Fig. S1c). While oxidative damage is one of the causative mechanisms involved in cellular damage induced by metals, it is now clear that other redox processes participate as well. The intrinsic reactivity of xenobiotic metals with thiol and selenol groups (Supplementary Fig. S1d) and their capacity to displace essential metals (Supplementary Fig. S1e) are also central to their capacity to promote energy failure (mitochondrial dysfunction), protein damage/aggregation, and metabolic alterations that challenge neuro/glial function and survival and trigger excitotoxic and inflammatory processes (Supplementary Fig. S1f). Cells have the capacity to respond by

activating redox- or metal-dependent transcriptional regulation of antioxidant and anti-inflammatory responses (Supplementary Fig. S1g).

The aim of this review was to provide an integrated overview of the recent advances regarding how dysfunctional metal ion homeostasis of essential metals and exposure to xenobiotic metals alter cellular function to promote chronic neurodegeneration and neurotoxicity. Although the mechanisms involved in these processes are still being elucidated, the studies highlighted here are a starting point toward a better understanding of the pathological consequences of alterations in metal ion homeostasis, justifying the need of further studies regarding their metabolism and its impact on cellular homeostasis, function, and survival.

Acknowledgments

This work was supported by the National Institutes of Health Grant P20RR17675, Centers of Biomedical Research Excellence (COBRE), the Interdisciplinary Grant from the Research Council, the Life Sciences Grant Program of the University of Nebraska-Lincoln, the Mexican Academy of Sciences (AMC) (R.F.), and the National Council for Science and Technology in Mexico (CONACYT) *via* grant 221134 (L.Q.). PhD fellowships to Y.P. (308512) and C.G.-L. (290116) were from CONACYT. This work was performed in partial fulfillment of the requirements for the PhD degree in the posgrado en Ciencias Biomédicas at the Universidad Nacional Autónoma de México.

References

1. Aboud AA, Tidball AM, Kumar KK, Neely MD, Han B, Ess KC, Hong CC, Erikson KM, Hedera P, and Bowman AB. PARK2 patient neuroprogenitors show increased mitochondrial sensitivity to copper. *Neurobiol Dis* 73: 204–212, 2015.
2. Acosta-Cabronero J, Betts MJ, Cardenas-Blanco A, Yang S, and Nestor PJ. In vivo MRI mapping of brain iron deposition across the adult lifespan. *J Neurosci* 36: 364–374, 2016.
3. Adonaylo VN and Oteiza PI. Pb^{2+} promotes lipid oxidation and alterations in membrane physical properties. *Toxicology* 132: 19–32, 1999.
4. Aimo L and Oteiza PI. Zinc deficiency increases the susceptibility of human neuroblastoma cells to lead-induced activator protein-1 activation. *Toxicol Sci* 91: 184–191, 2006.
5. Al-Hilaly YK, Biasetti L, Blakeman BJ, Pollack SJ, Zibae S, Abdul-Sada A, Thorpe JR, Xue WF, and Serpell LC. The involvement of dityrosine crosslinking in α -synuclein assembly and deposition in Lewy bodies in Parkinson's disease. *Sci Rep* 6: 39171, 2016.
6. Alfonso-Prieto M, Vidossich P, and Rovira C. The reaction mechanisms of heme catalases: an atomistic view by ab initio molecular dynamics. *Arch Biochem Biophys* 525: 121–130, 2012.
7. Amri F, Ghouili I, Amri M, Carrier A, and Masmoudi-Kouki O. Neuroglobin protects astroglial cells from hydrogen peroxide-induced oxidative stress and apoptotic cell death. *J Neurochem* 140: 151–169, 2017.
8. Anandhan A, Rodriguez-Rocha H, Bohovych I, Griggs AM, Zavala-Flores L, Reyes-Reyes EM, Seravalli J,

- Stanciu LA, Lee J, Rochet JC, Khalimonchuk O, and Franco R. Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways. *Neurobiol Dis* 81: 76–92, 2015.
9. Anderson CT, Radford RJ, Zastrow ML, Zhang DY, Apfel UP, Lippard SJ, and Tzounopoulos T. Modulation of extrasynaptic NMDA receptors by synaptic and tonic zinc. *Proc Natl Acad Sci U S A* 112: E2705–E2714, 2015.
 10. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, and Chilcote TJ. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. *J Biol Chem* 281: 29739–29752, 2006.
 11. Antala S and Dempsey RE. The human ZIP4 transporter has two distinct binding affinities and mediates transport of multiple transition metals. *Biochemistry* 51: 963–973, 2012.
 12. Antonio MT, Corredor L, and Leret ML. Study of the activity of several brain enzymes like markers of the neurotoxicity induced by perinatal exposure to lead and/or cadmium. *Toxicol Lett* 143: 331–340, 2003.
 13. Aoyama K, Watabe M, and Nakaki T. Regulation of neuronal glutathione synthesis. *J Pharmacol Sci* 108: 227–238, 2008.
 14. Aschner M, Gannon M, and Kimelberg HK. Manganese uptake and efflux in cultured rat astrocytes. *J Neurochem* 58: 730–735, 1992.
 15. Aschner M, Yao CP, Allen JW, and Tan KH. Methylmercury alters glutamate transport in astrocytes. *Neurochem Int* 37: 199–206, 2000.
 16. Atamna H and Boyle K. Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. *Proc Natl Acad Sci U S A* 103: 3381–3386, 2006.
 17. Banci L, Bertini I, Cantini F, Kozyreva T, Massagni C, Palumaa P, Rubino JT, and Zovo K. Human superoxide dismutase 1 (hSOD1) maturation through interaction with human copper chaperone for SOD1 (hCCS). *Proc Natl Acad Sci U S A* 109: 13555–13560, 2012.
 18. Banci L, Bertini I, Ciofi-Baffoni S, Kozyreva T, Zovo K, and Palumaa P. Affinity gradients drive copper to cellular destinations. *Nature* 465: 645–648, 2010.
 19. Baranowska-Bosiacka I, Gutowska I, Marchlewicz M, Marchetti C, Kurzawski M, Dziedzic V, Kolasa A, Olszewska M, Rybicka M, Safranow K, Nowacki P, Wiszniewska B, and Chlubek D. Disrupted pro- and antioxidative balance as a mechanism of neurotoxicity induced by perinatal exposure to lead. *Brain Res* 1435: 56–71, 2012.
 20. Barnes N, Tsivkovskii R, Tsivkovskaia N, and Lutsenko S. The copper-transporting ATPases, Menkes and Wilson disease proteins, have distinct roles in adult and developing cerebellum. *J Biol Chem* 280: 9640–9645, 2005.
 21. Barritt JD and Viles JH. Truncated amyloid-beta(11–40/42) from Alzheimer disease binds Cu^{2+} with a femtomolar affinity and influences fiber assembly. *J Biol Chem* 290: 27791–27802, 2015.
 22. Baumkötter F, Schmidt N, Vargas C, Schilling S, Weber R, Wagner K, Fiedler S, Klug W, Radzimanowski J, Nickolaus S, Keller S, Eggert S, Wild K, and Kins S. Amyloid precursor protein dimerization and synaptogenic function depend on copper binding to the growth factor-like domain. *J Neurosci* 34: 11159–11172, 2014.
 23. Baxter PS and Hardingham GE. Adaptive regulation of the brain's antioxidant defences by neurons and astrocytes. *Free Radic Biol Med* 100: 147–152, 2016.
 24. Becaria A, Lahiri DK, Bondy SC, Chen D, Hamadeh A, Li H, Taylor R, and Campbell A. Aluminum and copper in drinking water enhance inflammatory or oxidative events specifically in the brain. *J Neuroimmunol* 176: 16–23, 2006.
 25. Beck MW, Oh SB, Kerr RA, Lee HJ, Kim SH, Kim S, Jang M, Ruotolo BT, Lee J-Y, and Lim MH. A rationally designed small molecule for identifying an in vivo link between metal-amyloid-[small beta] complexes and the pathogenesis of Alzheimer's disease. *Chem Sci* 6: 1879–1886, 2015.
 26. Belanger M, Allaman I, and Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. *Cell Metab* 14: 724–738, 2011.
 27. Bell KF, Al-Mubarak B, Martel MA, McKay S, Wheelan N, Hasel P, Markus NM, Baxter P, Deighton RF, Serio A, Bilican B, Chowdhry S, Meakin PJ, Ashford ML, Wyllie DJ, Scannevin RH, Chandran S, Hayes JD, and Hardingham GE. Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2. *Nat Commun* 6: 7066, 2015.
 28. Bellingham SA, Cicciocioppo GD, Needham BE, Fodero LR, White AR, Masters CL, Cappai R, and Camakaris J. Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. *J Neurochem* 91: 423–428, 2004.
 29. Belloni-Olivi L, Marshall C, Laal B, Andrews GK, and Bressler J. Localization of zip1 and zip4 mRNA in the adult rat brain. *J Neurosci Res* 87: 3221–3230, 2009.
 30. Besecker B, Bao S, Bohacova B, Papp A, Sadee W, and Knoell DL. The human zinc transporter SLC39A8 (Zip8) is critical in zinc-mediated cytoprotection in lung epithelia. *Am J Physiol Lung Cell Mol Physiol* 294: L1127–L1136, 2008.
 31. Besser L, Chorin E, Sekler I, Silverman WF, Atkin S, Russell JT, and Hershfinkel M. Synaptically released zinc triggers metabotropic signaling via a zinc-sensing receptor in the hippocampus. *J Neurosci* 29: 2890–2901, 2009.
 32. Biagioli M, Pinto M, Cesselli D, Zaninello M, Lazarevic D, Roncaglia P, Simone R, Vlachouli C, Plessy C, Bertin N, Beltrami A, Kobayashi K, Gallo V, Santoro C, Ferrer I, Rivella S, Beltrami CA, Carninci P, Raviola E, and Gustincich S. Unexpected expression of alpha- and beta-globin in mesencephalic dopaminergic neurons and glial cells. *Proc Natl Acad Sci U S A* 106: 15454–15459, 2009.
 33. Binolfi A, Quintanar L, Bertoncini CW, Griesinger C, and Fernández CO. Bioinorganic chemistry of copper coordination to alpha-synuclein: relevance to Parkinson's disease. *Coord Chem Rev* 256: 2188–2201, 2012.
 34. Binolfi A, Rasia RM, Bertoncini CW, Ceolin M, Zweckstetter M, Griesinger C, Jovin TM, and Fernandez CO. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. *J Am Chem Soc* 128: 9893–9901, 2006.

35. Bjorkblom B, Adilbayeva A, Maple-Groden J, Piston D, Okvist M, Xu XM, Brede C, Larsen JP, and Moller SG. Parkinson disease protein DJ-1 binds metals and protects against metal-induced cytotoxicity. *J Biol Chem* 288: 22809–22820, 2013.
36. Bolin CM, Basha R, Cox D, Zawia NH, Maloney B, Lahiri DK, and Cardozo-Pelaez F. Exposure to lead and the developmental origin of oxidative DNA damage in the aging brain. *FASEB J* 20: 788–790, 2006.
37. Bondy SC. Low levels of aluminum can lead to behavioral and morphological changes associated with Alzheimer's disease and age-related neurodegeneration. *Neurotoxicology* 52: 222–229, 2016.
38. Bourassa MW, Leskovjan AC, Tappero RV, Farquhar ER, Colton CA, Van Nostrand WE, and Miller LM. Elevated copper in the amyloid plaques and iron in the cortex are observed in mouse models of Alzheimer's disease that exhibit neurodegeneration. *Biomed Spectrosc Imaging* 2: 129–139, 2013.
39. Bousejra-ElGarah F, Bijani C, Coppel Y, Faller P, and Hureau C. Iron(II) binding to amyloid-beta, the Alzheimer's peptide. *Inorg Chem* 50: 9024–9030, 2011.
40. Bove J, Martinez-Vicente M, Dehay B, Perier C, Recasens A, Bombrun A, Antonsson B, and Vila M. BAX channel activity mediates lysosomal disruption linked to Parkinson disease. *Autophagy* 10: 889–900, 2014.
41. Brose J, La Fontaine S, Wedd AG, and Xiao Z. Redox sulfur chemistry of the copper chaperone Atox1 is regulated by the enzyme glutaredoxin 1, the reduction potential of the glutathione couple GSSG/2GSH and the availability of Cu(I). *Metallomics* 6: 793–808, 2014.
42. Bucossi S, Ventriglia M, Panetta V, Salustri C, Pasqualetti P, Mariani S, Siotto M, Rossini PM, and Squitti R. Copper in Alzheimer's disease: a meta-analysis of serum, plasma, and cerebrospinal fluid studies. *J Alzheimers Dis* 24: 175–185, 2011.
43. Burmester T, Weich B, Reinhardt S, and Hankeln T. A vertebrate globin expressed in the brain. *Nature* 407: 520–523, 2000.
44. Calatayud M, Barrios JA, Velez D, and Devesa V. In vitro study of transporters involved in intestinal absorption of inorganic arsenic. *Chem Res Toxicol* 25: 446–453, 2012.
45. Calderon J, Navarro ME, Jimenez-Capdeville ME, Santos-Diaz MA, Golden A, Rodriguez-Leyva I, Borja-Aburto V, and Diaz-Barriga F. Exposure to arsenic and lead and neuropsychological development in Mexican children. *Environ Res* 85: 69–76, 2001.
46. Calvo IA, Boronat S, Domenech A, Garcia-Santamarina S, Ayte J, and Hidalgo E. Dissection of a redox relay: H₂O₂-dependent activation of the transcription factor Pap1 through the peroxidatic Tpx1-thioredoxin cycle. *Cell Rep* 5: 1413–1424, 2013.
47. Carmona F, Palacios Ò, Gálvez N, Cuesta R, Atrian S, Capdevila M, and Domínguez-Vera JM. Ferritin iron uptake and release in the presence of metals and metalloproteins: chemical implications in the brain. *Coord Chem Rev* 257: 2752–2764, 2013.
48. Castro-Coronel Y, Del Razo LM, Huerta M, Hernandez-Lopez A, Ortega A, and Lopez-Bayghen E. Arsenite exposure downregulates EAAT1/GLAST transporter expression in glial cells. *Toxicol Sci* 122: 539–550, 2011.
49. Chandran L and Cataldo R. Lead poisoning: basics and new developments. *Pediatr Rev* 31: 399–405; quiz 406, 2010.
50. Chang YY, Kuo TC, Hsu CH, Hou DR, Kao YH, and Huang RN. Characterization of the role of protein-cysteine residues in the binding with sodium arsenite. *Arch Toxicol* 86: 911–922, 2012.
51. Cheah JH, Kim SF, Hester LD, Clancy KW, Patterson SE, 3rd, Papadopoulos V, and Snyder SH. NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexas1. *Neuron* 51: 431–440, 2006.
52. Cheignon C, Jones M, Atrian-Blasco E, Kieffer I, Faller P, Collin F, and Hureau C. Identification of key structural features of the elusive Cu-A[small beta] complex that generates ROS in Alzheimer's disease. *Chem Sci* 8: 5107–5118, 2017.
53. Chen L, Hambright WS, Na R, and Ran Q. Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. *J Biol Chem* 290: 28097–28106, 2015.
54. Chen P, Chakraborty S, Mukhopadhyay S, Lee E, Pao-liello MM, Bowman AB, and Aschner M. Manganese homeostasis in the nervous system. *J Neurochem* 134: 601–610, 2015.
55. Chiang S, Kovacevic Z, Sahni S, Lane DJ, Merlot AM, Kalinowski DS, Huang ML, and Richardson DR. Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia. *Clin Sci (Lond)* 130: 853–870, 2016.
56. Chien WL, Lee TR, Hung SY, Kang KH, Lee MJ, and Fu WM. Impairment of oxidative stress-induced heme oxygenase-1 expression by the defect of Parkinson-related gene of PINK1. *J Neurochem* 117: 643–653, 2011.
57. Cho HH, Cahill CM, Vanderburg CR, Scherzer CR, Wang B, Huang X, and Rogers JT. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. *J Biol Chem* 285: 31217–31232, 2010.
58. Choi BS and Zheng W. Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. *Brain Res* 1248: 14–21, 2009.
59. Choi DK, Pennathur S, Perier C, Tieu K, Teismann P, Wu DC, Jackson-Lewis V, Vila M, Vonsattel JP, Heinecke JW, and Przedborski S. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. *J Neurosci* 25: 6594–6600, 2005.
60. Codazzi F, Pelizzoni I, Zacchetti D, and Grohovaz F. Iron entry in neurons and astrocytes: a link with synaptic activity. *Front Mol Neurosci* 8: 18, 2015.
61. Connor JR, Menzies SL, St Martin SM, and Mufson EJ. Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. *J Neurosci Res* 27: 595–611, 1990.
62. Coon S, Stark A, Peterson E, Gloi A, Kortsha G, Pounds J, Chettle D, and Gorell J. Whole-body lifetime occupational lead exposure and risk of Parkinson's disease. *Environ Health Perspect* 114: 1872–1876, 2006.
63. Cruces-Sande A, Mendez-Alvarez E, and Soto-Otero R. Copper increases the ability of 6-hydroxydopamine to generate oxidative stress and the ability of ascorbate and glutathione to potentiate this effect: potential implications in Parkinson's disease. *J Neurochem* 141: 738–749, 2017.
64. Culotta VC, Yang M, and O'Halloran TV. Activation of superoxide dismutases: putting the metal to the pedal. *Biochim Biophys Acta* 1763: 747–758, 2006.
65. Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, Chinnery PF, Coulthard A, Jackson MJ, Jackson AP, McHale DP, Hay D, Barker WA, Markham AF, Bates

- D, Curtis A, and Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. *Nat Genet* 28: 350–354, 2001.
66. D'Ambrosi N and Rossi L. Copper at synapse: release, binding and modulation of neurotransmission. *Neurochem Int* 90: 36–45, 2015.
67. Danielson SR and Andersen JK. Oxidative and nitrative protein modifications in Parkinson's disease. *Free Radic Biol Med* 44: 1787–1794, 2008.
68. Dapul H and Laraque D. Lead poisoning in children. *Adv Pediatr* 61: 313–333, 2014.
69. Das A, Nag S, Mason AB, and Barroso MM. Endosome-mitochondria interactions are modulated by iron release from transferrin. *J Cell Biol* 214: 831–845, 2016.
70. Davies KM, Bohic S, Carmona A, Ortega R, Cottam V, Hare DJ, Finberg JP, Reyes S, Halliday GM, Mercer JF, and Double KL. Copper pathology in vulnerable brain regions in Parkinson's disease. *Neurobiol Aging* 35: 858–866, 2014.
71. Davies MJ. Protein oxidation and peroxidation. *Biochem J* 473: 805–825, 2016.
72. Davis LE, Kornfeld M, Mooney HS, Fiedler KJ, Haaland KY, Orrison WW, Cernichiari E, and Clarkson TW. Methylmercury poisoning: long-term clinical, radiological, toxicological, and pathological studies of an affected family. *Ann Neurol* 35: 680–688, 1994.
73. Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, and Vila M. Pathogenic lysosomal depletion in Parkinson's disease. *J Neurosci* 30: 12535–12544, 2010.
74. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, and Marsden CD. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. *Brain* 114 (Pt 4): 1953–1975, 1991.
75. Dikiy I and Eliezer D. N-terminal acetylation stabilizes N-terminal helicity in lipid- and micelle-bound alpha-synuclein and increases its affinity for physiological membranes. *J Biol Chem* 289: 3652–3665, 2014.
76. Ding L, Saunders RJ, Drobna Z, Walton FS, Xun P, Thomas DJ, and Styblo M. Methylation of arsenic by recombinant human wild-type arsenic (+3 oxidation state) methyltransferase and its methionine 287 threonine (M287T) polymorph: role of glutathione. *Toxicol Appl Pharmacol* 264: 121–130, 2012.
77. Do Van B, Gouel F, Jonneaux A, Timmerman K, Gele P, Petraut M, Bastide M, Laloux C, Moreau C, Bordet R, Devos D, and Devedjian JC. Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC. *Neurobiol Dis* 94: 169–178, 2016.
78. Dodani SC, Firl A, Chan J, Nam CI, Aron AT, Onak CS, Ramos-Torres KM, Paek J, Webster CM, Feller MB, and Chang CJ. Copper is an endogenous modulator of neural circuit spontaneous activity. *Proc Natl Acad Sci U S A* 111: 16280–16285, 2014.
79. Donaldson J, McGregor D, and LaBella F. Manganese neurotoxicity: a model for free radical mediated neurodegeneration? *Can J Physiol Pharmacol* 60: 1398–1405, 1982.
80. Du K, Liu MY, Zhong X, and Wei MJ. Decreased circulating zinc levels in Parkinson's disease: a meta-analysis study. *Sci Rep* 7: 3902, 2017.
81. Duong TT, Witting PK, Antao ST, Parry SN, Kennerson M, Lai B, Vogt S, Lay PA, and Harris HH. Multiple protective activities of neuroglobin in cultured neuronal cells exposed to hypoxia re-oxygenation injury. *J Neurochem* 108: 1143–1154, 2009.
82. Dwivedi N, Flora G, Kushwaha P, and Flora SJ. Alpha-lipoic acid protects oxidative stress, changes in cholinergic system and tissue histopathology during co-exposure to arsenic-dichlorvos in rats. *Environ Toxicol Pharmacol* 37: 7–23, 2014.
83. Eckl PM and Bresgen N. Genotoxicity of lipid oxidation compounds. *Free Radic Biol Med* 111: 244–252, 2017.
84. Edwards M, Triantafyllidou S, and Best D. Elevated blood lead in young children due to lead-contaminated drinking water: Washington, DC, 2001–2004. *Environ Sci Technol* 43: 1618–1623, 2009.
85. Escudero-Lourdes C. Toxicity mechanisms of arsenic that are shared with neurodegenerative diseases and cognitive impairment: role of oxidative stress and inflammatory responses. *Neurotoxicology* 53: 223–235, 2016.
86. Eskici G and Axelsen PH. Copper and oxidative stress in the pathogenesis of Alzheimer's disease. *Biochemistry* 51: 6289–6311, 2012.
87. Espinosa de los Monteros A, Chiapelli F, Fisher RS, and de Vellis J. Transferrin: an early marker of oligodendrocytes in culture. *Int J Dev Neurosci* 6: 167–175, 1988.
88. Esposito G, Vos M, Vilain S, Swerts J, De Sousa Valadas J, Van Meensel S, Schaap O, and Verstreken P. Aconitase causes iron toxicity in *Drosophila* pink1 mutants. *PLoS Genet* 9: e1003478, 2013.
89. Farina M, Avila DS, da Rocha JB, and Aschner M. Metals, oxidative stress and neurodegeneration: a focus on iron, manganese and mercury. *Neurochem Int* 62: 575–594, 2013.
90. Farzan SF, Karagas MR, and Chen Y. In utero and early life arsenic exposure in relation to long-term health and disease. *Toxicol Appl Pharmacol* 272: 384–390, 2013.
91. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, and Hirsch EC. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. *J Neurochem* 86: 1142–1148, 2003.
92. Fernandes J, Hao L, Bijli KM, Chandler JD, Orr M, Hu X, Jones DP, and Go YM. From the cover: manganese stimulates mitochondrial H₂O₂ production in SH-SY5Y human neuroblastoma cells over physiologic as well as toxicologic range. *Toxicol Sci* 155: 213–223, 2017.
93. Ferreira AM, Ciriolo MR, Marcocci L, and Rotilio G. Copper(I) transfer into metallothionein mediated by glutathione. *Biochem J* 292 (Pt 3): 673–676, 1993.
94. Ferrer I, Gomez A, Carmona M, Huesa G, Porta S, Riera-Codina M, Biagioli M, Gustincich S, and Aso E. Neuronal hemoglobin is reduced in Alzheimer's disease, argyrophilic grain disease, Parkinson's disease, and dementia with Lewy bodies. *J Alzheimers Dis* 23: 537–550, 2011.
95. Filipov NM, Seegal RF, and Lawrence DA. Manganese potentiates in vitro production of proinflammatory cytokines and nitric oxide by microglia through a nuclear factor kappa B-dependent mechanism. *Toxicol Sci* 84: 139–148, 2005.
96. Finkel T. Signal transduction by reactive oxygen species. *J Cell Biol* 194: 7–15, 2011.
97. Flora SJ. Arsenic-induced oxidative stress and its reversibility. *Free Radic Biol Med* 51: 257–281, 2011.
98. Flora SJ, Pande M, and Mehta A. Beneficial effect of combined administration of some naturally occurring antioxidants (vitamins) and thiol chelators in the treatment

- of chronic lead intoxication. *Chem Biol Interact* 145: 267–280, 2003.
99. Flora SJ, Saxena G, and Mehta A. Reversal of lead-induced neuronal apoptosis by chelation treatment in rats: role of reactive oxygen species and intracellular Ca(2+). *J Pharmacol Exp Ther* 322: 108–116, 2007.
 100. Forman HJ. Redox signaling: an evolution from free radicals to aging. *Free Radic Biol Med* 97: 398–407, 2016.
 101. Forman HJ, Davies MJ, Kramer AC, Miotto G, Zaccarin M, Zhang H, and Ursini F. Protein cysteine oxidation in redox signaling: caveats on sulfenic acid detection and quantification. *Arch Biochem Biophys* 617: 26–37, 2017.
 102. Fox JH, Kama JA, Lieberman G, Chopra R, Dorsey K, Chopra V, Volitakis I, Cherny RA, Bush AI, and Hersch S. Mechanisms of copper ion mediated Huntington's disease progression. *PLoS One* 2: e334, 2007.
 103. Fraga CG. Relevance, essentiality and toxicity of trace elements in human health. *Mol Aspects Med* 26: 235–244, 2005.
 104. Franco JL, Posser T, Dunkley PR, Dickson PW, Mattos JJ, Martins R, Bainy AC, Marques MR, Dafre AL, and Farina M. Methylmercury neurotoxicity is associated with inhibition of the antioxidant enzyme glutathione peroxidase. *Free Radic Biol Med* 47: 449–457, 2009.
 105. Franco R and Cidlowski JA. Glutathione efflux and cell death. *Antioxid Redox Signal* 17: 1694–1713, 2012.
 106. Gao G and Chang YZ. Mitochondrial ferritin in the regulation of brain iron homeostasis and neurodegenerative diseases. *Front Pharmacol* 5: 19, 2014.
 107. Garcia-Chavez E, Jimenez I, Segura B, and Del Razo LM. Lipid oxidative damage and distribution of inorganic arsenic and its metabolites in the rat nervous system after arsenite exposure: influence of alpha tocopherol supplementation. *Neurotoxicology* 27: 1024–1031, 2006.
 108. Garcia-Chavez E, Santamaria A, Diaz-Barriga F, Mandeville P, Juarez BI, and Jimenez-Capdeville ME. Arsenite-induced formation of hydroxyl radical in the striatum of awake rats. *Brain Res* 976: 82–89, 2003.
 109. Garcia-Nogales P, Almeida A, and Bolanos JP. Peroxynitrite protects neurons against nitric oxide-mediated apoptosis. A key role for glucose-6-phosphate dehydrogenase activity in neuroprotection. *J Biol Chem* 278: 864–874, 2003.
 110. Gasperini L, Meneghetti E, Pastore B, Benetti F, and Legname G. Prion protein and copper cooperatively protect neurons by modulating NMDA receptor through S-nitrosylation. *Antioxid Redox Signal* 22: 772–784, 2015.
 111. Gavin CE, Gunter KK, and Gunter TE. Mn²⁺ sequestration by mitochondria and inhibition of oxidative phosphorylation. *Toxicol Appl Pharmacol* 115: 1–5, 1992.
 112. Ghosh C, Seal M, Mukherjee S, and Ghosh Dey S. Alzheimer's disease: a heme- α perspective. *Acc Chem Res* 48: 2556–2564, 2015.
 113. Girijashanker K, He L, Soleimani M, Reed JM, Li H, Liu Z, Wang B, Dalton TP, and Nebert DW. Slc39a14 gene encodes ZIP14, a metal/bicarbonate symporter: similarities to the ZIP8 transporter. *Mol Pharmacol* 73: 1413–1423, 2008.
 114. Giroto S, Cendron L, Bisaglia M, Tessari I, Mammi S, Zanotti G, and Bubacco L. DJ-1 is a copper chaperone acting on SOD1 activation. *J Biol Chem* 289: 10887–10899, 2014.
 115. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, and Richardson RJ. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. *Neurotoxicology* 20: 239–247, 1999.
 116. Grandjean P. Regional distribution of lead in human brains. *Toxicol Lett* 2: 65–69, 1978.
 117. Gu C, Chen S, Xu X, Zheng L, Li Y, Wu K, Liu J, Qi Z, Han D, Chen G, and Huo X. Lead and cadmium synergistically enhance the expression of divalent metal transporter 1 protein in central nervous system of developing rats. *Neurochem Res* 34: 1150–1156, 2009.
 118. Gundert-Remy U, Damm G, Foth H, Freyberger A, Gebel T, Golka K, Rohl C, Schupp T, Wollin KM, and Hengstler JG. High exposure to inorganic arsenic by food: the need for risk reduction. *Arch Toxicol* 89: 2219–2227, 2015.
 119. Gunther V, Lindert U, and Schaffner W. The taste of heavy metals: gene regulation by MTF-1. *Biochim Biophys Acta* 1823: 1416–1425, 2012.
 120. Halliwell B and Cross CE. Oxygen-derived species: their relation to human disease and environmental stress. *Environ Health Perspect* 102(Suppl 10): 5–12, 1994.
 121. Hambright WS, Fonseca RS, Chen L, Na R, and Ran Q. Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. *Redox Biol* 12: 8–17, 2017.
 122. Han M, Chang J, and Kim J. Loss of divalent metal transporter 1 function promotes brain copper accumulation and increases impulsivity. *J Neurochem* 138: 918–928, 2016.
 123. Hands SL, Mason R, Sajjad MU, Giorgini F, and Wytenbach A. Metallothioneins and copper metabolism are candidate therapeutic targets in Huntington's disease. *Biochem Soc Trans* 38: 552–558, 2010.
 124. Hanna-Attisha M and Kuehn BM. Pediatrician sees long road ahead for Flint after lead poisoning crisis. *JAMA* 315: 967–969, 2016.
 125. Hare DJ, Lee JK, Beavis AD, van Gramberg A, George J, Adlard PA, Finkelstein DI, and Doble PA. Three-dimensional atlas of iron, copper, and zinc in the mouse cerebrum and brainstem. *Anal Chem* 84: 3990–3997, 2012.
 126. Hashimoto M, Rockenstein E, Mante M, Mallory M, and Masliah E. beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. *Neuron* 32: 213–223, 2001.
 127. Hatori Y, Clasen S, Hasan NM, Barry AN, and Lutsenko S. Functional partnership of the copper export machinery and glutathione balance in human cells. *J Biol Chem* 287: 26678–26687, 2012.
 128. Hatori Y, Yan Y, Schmidt K, Furukawa E, Hasan NM, Yang N, Liu CN, Sockanathan S, and Lutsenko S. Neuronal differentiation is associated with a redox-regulated increase of copper flow to the secretory pathway. *Nat Commun* 7: 10640, 2016.
 129. He X and Ma Q. Induction of metallothionein I by arsenic via metal-activated transcription factor 1: critical role of C-terminal cysteine residues in arsenic sensing. *J Biol Chem* 284: 12609–12621, 2009.
 130. Higashi Y, Aratake T, Shimizu S, Shimizu T, Nakamura K, Tsuda M, Yawata T, Ueba T, and Saito M. Influence of extracellular zinc on M1 microglial activation. *Sci Rep* 7: 43778, 2017.

131. Hinkle PM, Kinsella PA, and Osterhoudt KC. Cadmium uptake and toxicity via voltage-sensitive calcium channels. *J Biol Chem* 262: 16333–16337, 1987.
132. Hodgkinson VL, Zhu S, Wang Y, Ladomersky E, Nickelson K, Weisman GA, Lee J, Gitlin JD, and Petris MJ. Autonomous requirements of the Menkes disease protein in the nervous system. *Am J Physiol Cell Physiol* 309: C660–C668, 2015.
133. Horning KJ, Caito SW, Tipps KG, Bowman AB, and Aschner M. Manganese is essential for neuronal health. *Annu Rev Nutr* 35: 71–108, 2015.
134. Howitt J, Putz U, Lackovic J, Doan A, Dorstyn L, Cheng H, Yang B, Chan-Ling T, Silke J, Kumar S, and Tan SS. Divalent metal transporter 1 (DMT1) regulation by Ndfp1 prevents metal toxicity in human neurons. *Proc Natl Acad Sci U S A* 106: 15489–15494, 2009.
135. Hsu PC and Guo YL. Antioxidant nutrients and lead toxicity. *Toxicology* 180: 33–44, 2002.
136. Hu Y, Su L, and Snow ET. Arsenic toxicity is enzyme specific and its effects on ligation are not caused by the direct inhibition of DNA repair enzymes. *Mutat Res* 408: 203–218, 1998.
137. Hu Z, Yu F, Gong P, Qiu Y, Zhou W, Cui Y, Li J, and Chen H. Subneurotoxic copper(II)-induced NF-kappaB-dependent microglial activation is associated with mitochondrial ROS. *Toxicol Appl Pharmacol* 276: 95–103, 2014.
138. Huang CC, Lesburg CA, Kiefer LL, Fierke CA, and Christianson DW. Reversal of the hydrogen bond to zinc ligand histidine-119 dramatically diminishes catalysis and enhances metal equilibration kinetics in carbonic anhydrase II. *Biochemistry* 35: 3439–3446, 1996.
139. Hughes MF. Arsenic toxicity and potential mechanisms of action. *Toxicol Lett* 133: 1–16, 2002.
140. Hureau C. Coordination of redox active metal ions to the amyloid precursor protein and to amyloid- β peptides involved in Alzheimer disease. Part 1: an overview. *Coord Chem Rev* 256: 2164–2174, 2012.
141. International Lead Management Center. 1999. OECD declaration on lead risk reduction. The LEAD Group, Inc. 2016. www.lead.org.au/lanv7n1/L71–L79.html (November 28 2016).
142. Isaya G. Mitochondrial iron-sulfur cluster dysfunction in neurodegenerative disease. *Front Pharmacol* 5: 29, 2014.
143. Ito K, Eguchi Y, Imagawa Y, Akai S, Mochizuki H, and Tsujimoto Y. MPP⁺ induces necrostatin-1- and ferrostatin-1-sensitive necrotic death of neuronal SH-SY5Y cells. *Cell Death Discov* 3: 17013, 2017.
144. Jeong SY and David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. *J Biol Chem* 278: 27144–27148, 2003.
145. Ji C and Kosman DJ. Molecular mechanisms of non-transferrin-bound and transferrin-bound iron uptake in primary hippocampal neurons. *J Neurochem* 133: 668–683, 2015.
146. Jia Y, Jeng JM, Sensi SL, and Weiss JH. Zn²⁺ currents are mediated by calcium-permeable AMPA/kainate channels in cultured murine hippocampal neurones. *J Physiol* 543: 35–48, 2002.
147. Jiang L, Garrick MD, Garrick LM, Zhao L, and Collins JF. Divalent metal transporter 1 (Dmt1) mediates copper transport in the duodenum of iron-deficient rats and when overexpressed in iron-deprived HEK-293 cells. *J Nutr* 143: 1927–1933, 2013.
148. Jimenez-Blasco D, Santofimia-Castano P, Gonzalez A, Almeida A, and Bolanos JP. Astrocyte NMDA receptors' activity sustains neuronal survival through a Cdk5-Nrf2 pathway. *Cell Death Differ* 22: 1877–1889, 2015.
149. Jin L, Wang J, Zhao L, Jin H, Fei G, Zhang Y, Zeng M, and Zhong C. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. *Brain* 134: 50–58, 2011.
150. Jomova K, Jenisova Z, Feszterova M, Baros S, Liska J, Hudecova D, Rhodes CJ, and Valko M. Arsenic: toxicity, oxidative stress and human disease. *J Appl Toxicol* 31: 95–107, 2011.
151. Jucaite A, Svenningsson P, Rinne JO, Cselenyi Z, Varnas K, Johnstrom P, Amini N, Kirjavainen A, Helin S, Minkwitz M, Kugler AR, Posener JA, Budd S, Halldin C, Varrone A, and Farde L. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. *Brain* 138: 2687–2700, 2015.
152. Julvez J and Grandjean P. Genetic susceptibility to methylmercury developmental neurotoxicity matters. *Front Genet* 4: 278, 2013.
153. Jusko TA, Henderson CR, Lanphear BP, Cory-Slechta DA, Parsons PJ, and Canfield RL. Blood lead concentrations <10 microg/dL and child intelligence at 6 years of age. *Environ Health Perspect* 116: 243–248, 2008.
154. Kalappa BI, Anderson CT, Goldberg JM, Lippard SJ, and Tzounopoulos T. AMPA receptor inhibition by synaptically released zinc. *Proc Natl Acad Sci U S A* 112: 15749–15754, 2015.
155. Kambe T, Tsuji T, Hashimoto A, and Itsumura N. The physiological, biochemical, and molecular roles of zinc transporters in zinc homeostasis and metabolism. *Physiol Rev* 95: 749–784, 2015.
156. Karki P, Webb A, Smith K, Johnson J, Jr., Lee K, Son DS, Aschner M, and Lee E. Yin Yang 1 is a repressor of glutamate transporter EAAT2, and it mediates manganese-induced decrease of EAAT2 expression in astrocytes. *Mol Cell Biol* 34: 1280–1289, 2014.
157. Kasten M, Tadic V, Klein C, Rocca WA, Savica R, Eric Ahlskog J, and Grossardt BR. Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. *Neurology* 74: 1655; author reply 1655–1656, 2010.
158. Khan K, Wasserman GA, Liu X, Ahmed E, Parvez F, Slavkovich V, Levy D, Mey J, van Geen A, Graziano JH, and Factor-Litvak P. Manganese exposure from drinking water and children's academic achievement. *Neurotoxicology* 33: 91–97, 2012.
159. Kiedrowski L. Cytosolic acidification and intracellular zinc release in hippocampal neurons. *J Neurochem* 121: 438–450, 2012.
160. Kim G, Weiss SJ, and Levine RL. Methionine oxidation and reduction in proteins. *Biochim Biophys Acta* 1840: 901–905, 2014.
161. Kim J and Wessling-Resnick M. Iron and mechanisms of emotional behavior. *J Nutr Biochem* 25: 1101–1107, 2014.
162. Kim YH and Koh JY. The role of NADPH oxidase and neuronal nitric oxide synthase in zinc-induced poly(ADP-ribose) polymerase activation and cell death in cortical culture. *Exp Neurol* 177: 407–418, 2002.
163. Koskenkorva-Frank TS, Weiss G, Koppenol WH, and Burckhardt S. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to in-

- duce oxidative and nitrosative stress. *Free Radic Biol Med* 65: 1174–1194, 2013.
164. Kuhn LC. Iron regulatory proteins and their role in controlling iron metabolism. *Metallomics* 7: 232–243, 2015.
 165. Kumar S and Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. *Toxicol Lett* 157: 175–188, 2005.
 166. Kumar V and Gill KD. Oxidative stress and mitochondrial dysfunction in aluminium neurotoxicity and its amelioration: a review. *Neurotoxicology* 41: 154–166, 2014.
 167. Lane DJ, Robinson SR, Czerwinski H, Bishop GM, and Lawen A. Two routes of iron accumulation in astrocytes: ascorbate-dependent ferrous iron uptake via the divalent metal transporter (DMT1) plus an independent route for ferric iron. *Biochem J* 432: 123–132, 2010.
 168. Langkammer C, Ropele S, Pirpamer L, Fazekas F, and Schmidt R. MRI for iron mapping in Alzheimer's disease. *Neurodegener Dis* 13: 189–191, 2014.
 169. Lau A, Zheng Y, Tao S, Wang H, Whitman SA, White E, and Zhang DD. Arsenic inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a p62-dependent manner. *Mol Cell Biol* 33: 2436–2446, 2013.
 170. Lautenschlager J, Kaminski CF, and Kaminski Schierle GS. alpha-Synuclein—regulator of exocytosis, endocytosis, or both? *Trends Cell Biol* 27: 468–479, 2017.
 171. Lee DW, Kaur D, Chinta SJ, Rajagopalan S, and Andersen JK. A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications for Parkinson's disease. *Antioxid Redox Signal* 11: 2083–2094, 2009.
 172. Lee JY, Cole TB, Palmiter RD, Suh SW, and Koh JY. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. *Proc Natl Acad Sci U S A* 99: 7705–7710, 2002.
 173. Leslie EM, Haimeur A, and Waalkes MP. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. *J Biol Chem* 279: 32700–32708, 2004.
 174. Leslie EM, Liu J, Klaassen CD, and Waalkes MP. Acquired cadmium resistance in metallothionein-I/II(-/-) knockout cells: role of the T-type calcium channel Cacnalpha1G in cadmium uptake. *Mol Pharmacol* 69: 629–639, 2006.
 175. Levesque PC and Atchison WD. Disruption of brain mitochondrial calcium sequestration by methylmercury. *J Pharmacol Exp Ther* 256: 236–242, 1991.
 176. Levi S, Corsi B, Bosio M, Invernizzi R, Volz A, Sanford D, Arosio P, and Drysdale J. A human mitochondrial ferritin encoded by an intronless gene. *J Biol Chem* 276: 24437–24440, 2001.
 177. Lewerenz J and Maher P. Basal levels of eIF2alpha phosphorylation determine cellular antioxidant status by regulating ATF4 and xCT expression. *J Biol Chem* 284: 1106–1115, 2009.
 178. Leyva-Illades D, Chen P, Zogzas CE, Hutchens S, Mercado JM, Swaim CD, Morrisett RA, Bowman AB, Aschner M, and Mukhopadhyay S. SLC30A10 is a cell surface-localized manganese efflux transporter, and parkinsonism-causing mutations block its intracellular trafficking and efflux activity. *J Neurosci* 34: 14079–14095, 2014.
 179. Li RC, Guo SZ, Lee SK, and Gozal D. Neuroglobin protects neurons against oxidative stress in global ischemia. *J Cereb Blood Flow Metab* 30: 1874–1882, 2010.
 180. Li RC, Pournafar F, Lee SK, Morris MW, Wang Y, and Gozal D. Neuroglobin protects PC12 cells against beta-amyloid-induced cell injury. *Neurobiol Aging* 29: 1815–1822, 2008.
 181. Li ZS, Szczykpa M, Lu YP, Thiele DJ, and Rea PA. The yeast cadmium factor protein (YCF1) is a vacuolar glutathione S-conjugate pump. *J Biol Chem* 271: 6509–6517, 1996.
 182. Lin AM, Chao PL, Fang SF, Chi CW, and Yang CH. Endoplasmic reticulum stress is involved in arsenite-induced oxidative injury in rat brain. *Toxicol Appl Pharmacol* 224: 138–146, 2007.
 183. Liu J, Liu Y, Powell DA, Waalkes MP, and Klaassen CD. Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. *Toxicology* 170: 55–62, 2002.
 184. Liu L, Jiang D, McDonald A, Hao Y, Millhauser GL, and Zhou F. Copper redox cycling in the prion protein depends critically on binding mode. *J Am Chem Soc* 133: 12229–12237, 2011.
 185. Liu X, Sullivan KA, Madl JE, Legare M, and Tjalkens RB. Manganese-induced neurotoxicity: the role of astroglial-derived nitric oxide in striatal interneuron degeneration. *Toxicol Sci* 91: 521–531, 2006.
 186. Liu Y, Barber DS, Zhang P, and Liu B. Complex II of the mitochondrial respiratory chain is the key mediator of divalent manganese-induced hydrogen peroxide production in microglia. *Toxicol Sci* 132: 298–306, 2013.
 187. Liu Z, Shen J, Carbrey JM, Mukhopadhyay R, Agre P, and Rosen BP. Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. *Proc Natl Acad Sci U S A* 99: 6053–6058, 2002.
 188. Liuzzi JP, Aydemir F, Nam H, Knutson MD, and Cousins RJ. Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. *Proc Natl Acad Sci U S A* 103: 13612–13617, 2006.
 189. Lo HS, Chiang HC, Lin AM, Chiang HY, Chu YC, and Kao LS. Synergistic effects of dopamine and Zn²⁺ on the induction of PC12 cell death and dopamine depletion in the striatum: possible implication in the pathogenesis of Parkinson's disease. *Neurobiol Dis* 17: 54–61, 2004.
 190. Logroscino G, Chen H, Wing A, and Ascherio A. Blood donations, iron stores, and risk of Parkinson's disease. *Mov Disord* 21: 835–838, 2006.
 191. Loikkanen JJ, Naarala J, and Savolainen KM. Modification of glutamate-induced oxidative stress by lead: the role of extracellular calcium. *Free Radic Biol Med* 24: 377–384, 1998.
 192. Loke SY, Siddiqi NJ, Alhomida AS, Kim HC, and Ong WY. Expression and localization of duodenal cytochrome b in the rat hippocampus after kainate-induced excitotoxicity. *Neuroscience* 245: 179–190, 2013.
 193. Lopachin RM and Decaprio AP. Protein adduct formation as a molecular mechanism in neurotoxicity. *Toxicol Sci* 86: 214–225, 2005.
 194. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, and Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. *J Neurol Sci* 158: 47–52, 1998.

195. Lu J and Holmgren A. The thioredoxin superfamily in oxidative protein folding. *Antioxid Redox Signal* 21: 457–470, 2014.
196. Lutsenko S. Human copper homeostasis: a network of interconnected pathways. *Curr Opin Chem Biol* 14: 211–217, 2010.
197. Lutsenko S. Copper trafficking to the secretory pathway. *Metallomics* 8: 840–852, 2016.
198. Maki RA, Tyurin VA, Lyon RC, Hamilton RL, DeKosky ST, Kagan VE, and Reynolds WF. Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease. *J Biol Chem* 284: 3158–3169, 2009.
199. Malaiyandi LM, Vergun O, Dineley KE, and Reynolds JJ. Direct visualization of mitochondrial zinc accumulation reveals uniporter-dependent and -independent transport mechanisms. *J Neurochem* 93: 1242–1250, 2005.
200. Mandal BK and Suzuki KT. Arsenic round the world: a review. *Talanta* 58: 201–235, 2002.
201. Manton WI, Kirkpatrick JB, and Cook JD. Does the choroid plexus really protect the brain from lead? *Lancet* 2: 351, 1984.
202. Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, and Maggio JE. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. *J Neurochem* 61: 1171–1174, 1993.
203. Mariani S, Ventriglia M, Simonelli I, Donno S, Bucossi S, Vernieri F, Melgari JM, Pasqualetti P, Rossini PM, and Squitti R. Fe and Cu do not differ in Parkinson's disease: a replication study plus meta-analysis. *Neurobiol Aging* 34: 632–633, 2013.
204. Marquez M, Blancas-Mejia LM, Campos A, Rojas L, Castaneda-Hernandez G, and Quintanar L. A bifunctional non-natural tetrapeptide modulates amyloid-beta peptide aggregation in the presence of Cu(II). *Metallomics* 6: 2189–2192, 2014.
205. Martinez-Finley EJ, Chakraborty S, Fretham SJ, and Aschner M. Cellular transport and homeostasis of essential and nonessential metals. *Metallomics* 4: 593–605, 2012.
206. Martinez-Finley EJ, Gavin CE, Aschner M, and Gunter TE. Manganese neurotoxicity and the role of reactive oxygen species. *Free Radic Biol Med* 62: 65–75, 2013.
207. Martinez L, Jimenez V, Garcia-Sepulveda C, Ceballos F, Delgado JM, Nino-Moreno P, Doniz L, Saavedra-Alanis V, Castillo CG, Santoyo ME, Gonzalez-Amaro R, and Jimenez-Capdeville ME. Impact of early developmental arsenic exposure on promoter CpG-island methylation of genes involved in neuronal plasticity. *Neurochem Int* 58: 574–581, 2011.
208. Maryon EB, Molloy SA, and Kaplan JH. Cellular glutathione plays a key role in copper uptake mediated by human copper transporter 1. *Am J Physiol Cell Physiol* 304: C768–C779, 2013.
209. Masoud AM, Bihagi SW, Machan JT, Zawia NH, and Renahan WE. Early-life exposure to lead (Pb) alters the expression of microRNA that target proteins associated with Alzheimer's disease. *J Alzheimers Dis* 51: 1257–1264, 2016.
210. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, and Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci U S A* 82: 4245–4249, 1985.
211. Mastroberardino PG, Hoffman EK, Horowitz MP, Betarbet R, Taylor G, Cheng D, Na HM, Gutekunst CA, Gearing M, Trojanowski JQ, Anderson M, Chu CT, Peng J, and Greenamyre JT. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. *Neurobiol Dis* 34: 417–431, 2009.
212. Matak P, Matak A, Moustafa S, Aryal DK, Benner EJ, Wetsel W, and Andrews NC. Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice. *Proc Natl Acad Sci U S A* 113: 3428–3435, 2016.
213. Mato S, Sanchez-Gomez MV, Bernal-Chico A, and Matute C. Cytosolic zinc accumulation contributes to excitotoxic oligodendroglial death. *Glia* 61: 750–764, 2013.
214. Mayes J, Tinker-Mill C, Kolosov O, Zhang H, Tabner BJ, and Allsop D. beta-Amyloid fibrils in Alzheimer disease are not inert when bound to copper ions but can degrade hydrogen peroxide and generate reactive oxygen species. *J Biol Chem* 289: 12052–12062, 2014.
215. McCarthy RC and Kosman DJ. Mechanistic analysis of iron accumulation by endothelial cells of the BBB. *Bio-metals* 25: 665–675, 2012.
216. McCarthy RC and Kosman DJ. Glial cell ceruloplasmin and hepcidin differentially regulate iron efflux from brain microvascular endothelial cells. *PLoS One* 9: e89003, 2014.
217. McCarthy RC and Kosman DJ. Iron transport across the blood-brain barrier: development, neurovascular regulation and cerebral amyloid angiopathy. *Cell Mol Life Sci* 72: 709–727, 2015.
218. McCarthy RC and Kosman DJ. Mechanisms and regulation of iron trafficking across the capillary endothelial cells of the blood-brain barrier. *Front Mol Neurosci* 8: 31, 2015.
219. McCarthy RC, Park YH, and Kosman DJ. sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin. *EMBO Rep* 15: 809–815, 2014.
220. McHugh PC, Wright JA, and Brown DR. Transcriptional regulation of the beta-synuclein 5'-promoter metal response element by metal transcription factor-1. *PLoS One* 6: e17354, 2011.
221. Meinerz DF, Branco V, Aschner M, Carvalho C, and Rocha JB. Diphenyl diselenide protects against methylmercury-induced inhibition of thioredoxin reductase and glutathione peroxidase in human neuroblastoma cells: a comparison with ebselen. *J Appl Toxicol* 37: 1073–1081, 2017.
222. Mellone M, Pelucchi S, Alberti L, Genazzani AA, Di Luca M, and Gardoni F. Zinc transporter-1: a novel NMDA receptor-binding protein at the postsynaptic density. *J Neurochem* 132: 159–168, 2015.
223. Meloni G, Sonois V, Delaine T, Guilloreau L, Gillet A, Teissie J, Faller P, and Vasak M. Metal swap between Zn7-metallothionein-3 and amyloid-beta-Cu protects against amyloid-beta toxicity. *Nat Chem Biol* 4: 366–372, 2008.
224. Menon AV, Chang J, and Kim J. Mechanisms of divalent metal toxicity in affective disorders. *Toxicology* 339: 58–72, 2016.
225. Meyer E, Kurian MA, and Hayflick SJ. Neurodegeneration with brain iron accumulation: genetic diversity and pathophysiological mechanisms. *Annu Rev Genomics Hum Genet* 16: 257–279, 2015.
226. Michael GJ, Esmailzadeh S, Moran LB, Christian L, Pearce RK, and Graeber MB. Up-regulation of me-

- tallothionein gene expression in parkinsonian astrocytes. *Neurogenetics* 12: 295–305, 2011.
227. Miotto MC, Rodriguez EE, Valiente-Gabioud AA, Torres-Monserrat V, Binolfi A, Quintanar L, Zweckstetter M, Griesinger C, and Fernandez CO. Site-specific copper-catalyzed oxidation of alpha-synuclein: tightening the link between metal binding and protein oxidative damage in Parkinson's disease. *Inorg Chem* 53: 4350–4358, 2014.
228. Miotto MC, Valiente-Gabioud AA, Rossetti G, Zweckstetter M, Carloni P, Selenko P, Griesinger C, Binolfi A, and Fernandez CO. Copper binding to the N-terminally acetylated, naturally occurring form of alpha-synuclein induces local helical folding. *J Am Chem Soc* 137: 6444–6447, 2015.
229. Mital M, Wezynfeld NE, Fraczyk T, Wiloch MZ, Wawrzyniak UE, Bonna A, Tumpach C, Barnham KJ, Haigh CL, Bal W, and Drew SC. A functional role for abeta in metal homeostasis? N-truncation and high-affinity copper binding. *Angew Chem Int Ed Engl* 54: 10460–10464, 2015.
230. Mizumura A, Watanabe T, Kobayashi Y, and Hirano S. Identification of arsenite and arsenic diglutathione-binding proteins in human hepatocarcinoma cells. *Toxicol Appl Pharmacol* 242: 119–125, 2010.
231. Monnot AD, Zheng G, and Zheng W. Mechanism of copper transport at the blood-cerebrospinal fluid barrier: influence of iron deficiency in an in vitro model. *Exp Biol Med (Maywood)* 237: 327–333, 2012.
232. Moos T. Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system. *J Comp Neurol* 375: 675–692, 1996.
233. Mori N, Yasutake A, and Hirayama K. Comparative study of activities in reactive oxygen species production/defense system in mitochondria of rat brain and liver, and their susceptibility to methylmercury toxicity. *Arch Toxicol* 81: 769–776, 2007.
234. Moriarty GM, Minetti CA, Remeta DP, and Baum J. A revised picture of the Cu(II)-alpha-synuclein complex: the role of N-terminal acetylation. *Biochemistry* 53: 2815–2817, 2014.
235. Morken TS, Sonnewald U, Aschner M, and Syversen T. Effects of methylmercury on primary brain cells in mono- and co-culture. *Toxicol Sci* 87: 169–175, 2005.
236. Moshtaghi AA, Ani M, Aghadavod E, and Fazilati M. Protective effects of selenium and zinc on changes in catecholamine levels of brain regions in lead intoxicated rat. *Pak J Biol Sci* 10: 2964–2967, 2007.
237. Munoz P, Humeres A, Elgueta C, Kirkwood A, Hidalgo C, and Nunez MT. Iron mediates N-methyl-D-aspartate receptor-dependent stimulation of calcium-induced pathways and hippocampal synaptic plasticity. *J Biol Chem* 286: 13382–13392, 2011.
238. Naarala JT, Loikkanen JJ, Ruotsalainen MH, and Savolainen KM. Lead amplifies glutamate-induced oxidative stress. *Free Radic Biol Med* 19: 689–693, 1995.
239. Nagababu E and Rifkind JM. Heme degradation by reactive oxygen species. *Antioxid Redox Signal* 6: 967–978, 2004.
240. Nagasawa K, Ito S, Kakuda T, Nagai K, Tamai I, Tsuji A, and Fujimoto S. Transport mechanism for aluminum citrate at the blood-brain barrier: kinetic evidence implies involvement of system Xc- in immortalized rat brain endothelial cells. *Toxicol Lett* 155: 289–296, 2005.
241. Nava-Ruiz C, Mendez-Armenta M, and Rios C. Lead neurotoxicity: effects on brain nitric oxide synthase. *J Mol Histol* 43: 553–563, 2012.
242. Neal AP and Guilarte TR. Molecular neurobiology of lead (Pb(2+)): effects on synaptic function. *Mol Neurobiol* 42: 151–160, 2010.
243. Negishi T, Takahashi M, Matsunaga Y, Hirano S, and Tashiro T. Diphenylarsinic acid increased the synthesis and release of neuroactive and vasoactive peptides in rat cerebellar astrocytes. *J Neuropathol Exp Neurol* 71: 468–479, 2012.
244. Nelson-Mora J, Escobar ML, Rodríguez-Durán L, Mas-sieu L, Montiel T, Rodríguez VM, Hernández-Mercado K, and Gonshebb ME. Gestational exposure to inorganic arsenic (iAs3+) alters glutamate disposition in the mouse hippocampus and ionotropic glutamate receptor expression leading to memory impairment. *Arch Toxicol* 92: 1037–1048, 2018.
245. Nemeti B, Regonesi ME, Tortora P, and Gregus Z. Polynucleotide phosphorylase and mitochondrial ATP synthase mediate reduction of arsenate to the more toxic arsenite by forming arsenylated analogues of ADP and ATP. *Toxicol Sci* 117: 270–281, 2010.
246. Nishito Y, Tsuji N, Fujishiro H, Takeda TA, Yamazaki T, Teranishi F, Okazaki F, Matsunaga A, Tuschl K, Rao R, Kono S, Miyajima H, Narita H, Himeno S, and Kambe T. Direct comparison of manganese detoxification/efflux proteins and molecular characterization of ZnT10 protein as a manganese transporter. *J Biol Chem* 291: 14773–14787, 2016.
247. Nolte C, Gore A, Sekler I, Kresse W, Hershfinkel M, Hoffmann A, Kettenmann H, and Moran A. ZnT-1 expression in astroglial cells protects against zinc toxicity and slows the accumulation of intracellular zinc. *Glia* 48: 145–155, 2004.
248. Nordberg G, Fowler BA, and Nordberg M. *Handbook on the Toxicology of Metals*. Amsterdam: Academic Press, 2014, p. 1 online resource.
249. Ogra Y, Tejima A, Hatakeyama N, Shiraiwa M, Wu S, Ishikawa T, Yawata A, Anan Y, and Suzuki N. Changes in intracellular copper concentration and copper-regulating gene expression after PC12 differentiation into neurons. *Sci Rep* 6: 33007, 2016.
250. Oken E and Bellinger DC. Fish consumption, methylmercury and child neurodevelopment. *Curr Opin Pediatr* 20: 178–183, 2008.
251. Olivieri S, Conti A, Iannaccone S, Cannistraci CV, Campanella A, Barbariga M, Codazzi F, Pelizzoni I, Magnani G, Pesca M, Franciotta D, Cappa SF, and Alessio M. Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. *J Neurosci* 31: 18568–18577, 2011.
252. Olsen LF, Issinger OG, and Guerra B. The Yin and Yang of redox regulation. *Redox Rep* 18: 245–252, 2013.
253. Omata Y, Salvador GA, Supasai S, Keenan AH, and Oteiza PI. Decreased zinc availability affects glutathione metabolism in neuronal cells and in the developing brain. *Toxicol Sci* 133: 90–100, 2013.
254. Ortega R, Carmona A, Roudeau S, Perrin L, Ducic T, Carboni E, Bohic S, Cloetens P, and Lingor P. alpha-Synuclein over-expression induces increased iron accumulation and redistribution in iron-exposed neurons. *Mol Neurobiol* 53: 1925–1934, 2016.

255. Oteiza PI. Zinc and the modulation of redox homeostasis. *Free Radic Biol Med* 53: 1748–1759, 2012.
256. Pachauri V, Saxena G, Mehta A, Mishra D, and Flora SJ. Combinational chelation therapy abrogates lead-induced neurodegeneration in rats. *Toxicol Appl Pharmacol* 240: 255–264, 2009.
257. Pan R and Liu KJ. ZNT-1 expression reduction enhances free zinc accumulation in astrocytes after ischemic stroke. *Acta Neurochir Suppl* 121: 257–261, 2016.
258. Pande M and Flora SJ. Lead induced oxidative damage and its response to combined administration of alpha-lipoic acid and succimers in rats. *Toxicology* 177: 187–196, 2002.
259. Park JS, Koentjoro B, Veivers D, Mackay-Sim A, and Sue CM. Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction. *Hum Mol Genet* 23: 2802–2815, 2014.
260. Parvez F, Wasserman GA, Factor-Litvak P, Liu X, Slavkovich V, Siddique AB, Sultana R, Sultana R, Islam T, Levy D, Mey JL, van Geen A, Khan K, Kline J, Ahsan H, and Graziano JH. Arsenic exposure and motor function among children in Bangladesh. *Environ Health Perspect* 119: 1665–1670, 2011.
261. Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, and David S. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. *J Neurosci* 22: 6578–6586, 2002.
262. Patel M. Targeting oxidative stress in central nervous system disorders. *Trends Pharmacol Sci* 37: 768–778, 2016.
263. Pauly PC and Harris DA. Copper stimulates endocytosis of the prion protein. *J Biol Chem* 273: 33107–33110, 1998.
264. Pedersen JT, Chen SW, Borg CB, Ness S, Bahl JM, Heegaard NH, Dobson CM, Hemmingsen L, Cremades N, and Teilmann K. Amyloid-beta and alpha-synuclein decrease the level of metal-catalyzed reactive oxygen species by radical scavenging and redox silencing. *J Am Chem Soc* 138: 3966–3969, 2016.
265. Pelizzoni I, Zacchetti D, Campanella A, Grohovaz F, and Codazzi F. Iron uptake in quiescent and inflammation-activated astrocytes: a potentially neuroprotective control of iron burden. *Biochim Biophys Acta* 1832: 1326–1333, 2013.
266. Pelizzoni I, Zacchetti D, Smith CP, Grohovaz F, and Codazzi F. Expression of divalent metal transporter 1 in primary hippocampal neurons: reconsidering its role in non-transferrin-bound iron influx. *J Neurochem* 120: 269–278, 2012.
267. Penugonda S, Mare S, Lutz P, Banks WA, and Ercal N. Potentiation of lead-induced cell death in PC12 cells by glutamate: protection by N-acetylcysteine amide (NACA), a novel thiol antioxidant. *Toxicol Appl Pharmacol* 216: 197–205, 2006.
268. Perkins A, Nelson KJ, Parsonage D, Poole LB, and Karplus PA. Peroxiredoxins: guardians against oxidative stress and modulators of peroxide signaling. *Trends Biochem Sci* 40: 435–445, 2015.
269. Perrin L, Roudeau S, Carmona A, Domart F, Petersen JD, Bohic S, Yang Y, Cloetens P, and Ortega R. Zinc and copper effects on stability of tubulin and actin networks in dendrites and spines of hippocampal neurons. *ACS Chem Neurosci* 8: 1490–1499, 2017.
270. Philbert MA, Billingsley ML, and Reuhl KR. Mechanisms of injury in the central nervous system. *Toxicol Pathol* 28: 43–53, 2000.
271. Pichler I, Del Greco MF, Gogele M, Lill CM, Bertram L, Do CB, Eriksson N, Foroud T, Myers RH, Nalls M, Keller MF, Benyamin B, Whitfield JB, Pramstaller PP, Hicks AA, Thompson JR, and Minelli C. Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. *PLoS Med* 10: e1001462, 2013.
272. Pietsch EC, Chan JY, Torti FM, and Torti SV. Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. *J Biol Chem* 278: 2361–2369, 2003.
273. Portelius E, Bogdanovic N, Gustavsson MK, Volkman I, Brinkmalm G, Zetterberg H, Winblad B, and Blennow K. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. *Acta Neuropathol* 120: 185–193, 2010.
274. Prakash C and Kumar V. Arsenic-induced mitochondrial oxidative damage is mediated by decreased PGC-1alpha expression and its downstream targets in rat brain. *Chem Biol Interact* 256: 228–235, 2016.
275. Prakash C, Soni M, and Kumar V. Biochemical and molecular alterations following arsenic-induced oxidative stress and mitochondrial dysfunction in rat brain. *Biol Trace Elem Res* 167: 121–129, 2015.
276. Prakash C, Soni M, and Kumar V. Mitochondrial oxidative stress and dysfunction in arsenic neurotoxicity: a review. *J Appl Toxicol* 36: 179–188, 2016.
277. Prasanthi RP, Devi CB, Basha DC, Reddy NS, and Reddy GR. Calcium and zinc supplementation protects lead (Pb)-induced perturbations in antioxidant enzymes and lipid peroxidation in developing mouse brain. *Int J Dev Neurosci* 28: 161–167, 2010.
278. Qian J, Xu K, Yoo J, Chen TT, Andrews G, and Noebels JL. Knockout of Zn transporters Zip-1 and Zip-3 attenuates seizure-induced CA1 neurodegeneration. *J Neurosci* 31: 97–104, 2011.
279. Qu W and Waalkes MP. Metallothionein blocks oxidative DNA damage induced by acute inorganic arsenic exposure. *Toxicol Appl Pharmacol* 282: 267–274, 2015.
280. Ramos-Chavez LA, Rendon-Lopez CR, Zepeda A, Silva-Adaya D, Del Razo LM, and Gonsebatt ME. Neurological effects of inorganic arsenic exposure: altered cysteine/glutamate transport, NMDA expression and spatial memory impairment. *Front Cell Neurosci* 9: 21, 2015.
281. Ramos D, Mar D, Ishida M, Vargas R, Gaite M, Montgomery A, and Linder MC. Mechanism of copper uptake from blood plasma ceruloplasmin by mammalian cells. *PLoS One* 11: e0149516, 2016.
282. Reczek CR and Chandel NS. ROS-dependent signal transduction. *Curr Opin Cell Biol* 33: 8–13, 2015.
283. Reddy GR and Zawia NH. Lead exposure alters Egr-1 DNA-binding in the neonatal rat brain. *Int J Dev Neurosci* 18: 791–795, 2000.
284. Rehman K and Naranmandura H. Arsenic metabolism and thioarsenicals. *Metallomics* 4: 881–892, 2012.
285. Rhodes SL, Buchanan DD, Ahmed I, Taylor KD, Lioriot MA, Sinsheimer JS, Bronstein JM, Elbaz A, Mellick GD, Rotter JJ, and Ritz B. Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin. *Neurobiol Dis* 62: 172–178, 2014.
286. Rogers B, Yakopson V, Teng ZP, Guo Y, and Regan RF. Heme oxygenase-2 knockout neurons are less vulnerable to hemoglobin toxicity. *Free Radic Biol Med* 35: 872–881, 2003.
287. Rosado JL, Ronquillo D, Kordas K, Rojas O, Alatorre J, Lopez P, Garcia-Vargas G, Del Carmen Caamano M,

- Cebrian ME, and Stoltzfus RJ. Arsenic exposure and cognitive performance in Mexican schoolchildren. *Environ Health Perspect* 115: 1371–1375, 2007.
288. Roskams AJ and Connor JR. Aluminum access to the brain: a role for transferrin and its receptor. *Proc Natl Acad Sci U S A* 87: 9024–9027, 1990.
 289. Roth JA, Singleton S, Feng J, Garrick M, and Paradkar PN. Parkin regulates metal transport via proteasomal degradation of the 1B isoforms of divalent metal transporter 1. *J Neurochem* 113: 454–464, 2010.
 290. Rouault TA. Iron metabolism in the CNS: implications for neurodegenerative diseases. *Nat Rev Neurosci* 14: 551–564, 2013.
 291. Rouault TA. Mammalian iron-sulphur proteins: novel insights into biogenesis and function. *Nat Rev Mol Cell Biol* 16: 45–55, 2015.
 292. Rush T, Liu X, Nowakowski AB, Petering DH, and Lobner D. Glutathione-mediated neuroprotection against methylmercury neurotoxicity in cortical culture is dependent on MRP1. *Neurotoxicology* 33: 476–481, 2012.
 293. Saini N, Georgiev O, and Schaffner W. The parkin mutant phenotype in the fly is largely rescued by metal-responsive transcription factor (MTF-1). *Mol Cell Biol* 31: 2151–2161, 2011.
 294. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, Arredondo M, Duyckaerts C, Szadovitch V, Zhao L, Garrick LM, Nunez MT, Garrick MD, Raisman-Vozari R, and Hirsch EC. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. *Proc Natl Acad Sci U S A* 105: 18578–18583, 2008.
 295. Salim S. Oxidative stress and the central nervous system. *J Pharmacol Exp Ther* 360: 201–205, 2017.
 296. Samuel S, Kathirvel R, Jayavelu T, and Chinnakkannu P. Protein oxidative damage in arsenic induced rat brain: influence of DL- α -lipoic acid. *Toxicol Lett* 155: 27–34, 2005.
 297. Sanchez-Pena LC, Petrosyan P, Morales M, Gonzalez NB, Gutierrez-Ospina G, Del Razo LM, and Gonshebbat ME. Arsenic species, AS3MT amount, and AS3MT gene expression in different brain regions of mouse exposed to arsenite. *Environ Res* 110: 428–434, 2010.
 298. Sanders T, Liu Y, Buchner V, and Tchounwou PB. Neurotoxic effects and biomarkers of lead exposure: a review. *Rev Environ Health* 24: 15–45, 2009.
 299. Santos CR, Martinho A, Quintela T, and Goncalves I. Neuroprotective and neuroregenerative properties of metallothioneins. *IUBMB Life* 64: 126–135, 2012.
 300. Scheiber IF and Dringen R. Astrocyte functions in the copper homeostasis of the brain. *Neurochem Int* 62: 556–565, 2013.
 301. Schlieff ML, Craig AM, and Gitlin JD. NMDA receptor activation mediates copper homeostasis in hippocampal neurons. *J Neurosci* 25: 239–246, 2005.
 302. Schrader M and Fahimi HD. Peroxisomes and oxidative stress. *Biochim Biophys Acta* 1763: 1755–1766, 2006.
 303. Segawa S, Tatsumi N, Ohishi A, Nishida K, and Nagasawa K. Characterization of zinc uptake by mouse primary cultured astrocytes and microglia. *Metallomics* 7: 1067–1077, 2015.
 304. Sensi SL, Paoletti P, Koh JY, Aizenman E, Bush AI, and Hershfinkel M. The neurophysiology and pathology of brain zinc. *J Neurosci* 31: 16076–16085, 2011.
 305. Sensi SL, Ton-That D, Sullivan PG, Jonas EA, Gee KR, Kaczmarek LK, and Weiss JH. Modulation of mitochondrial function by endogenous Zn^{2+} pools. *Proc Natl Acad Sci U S A* 100: 6157–6162, 2003.
 306. Senut MC, Cingolani P, Sen A, Kruger A, Shaik A, Hirsch H, Suhr ST, and Ruden D. Epigenetics of early-life lead exposure and effects on brain development. *Epigenomics* 4: 665–674, 2012.
 307. Seo YA, Lopez V, and Kelleher SL. A histidine-rich motif mediates mitochondrial localization of ZnT2 to modulate mitochondrial function. *Am J Physiol Cell Physiol* 300: C1479–C1489, 2011.
 308. Shahzad R, Jones MR, Viles JH, and Jones CE. Endocytosis of the tachykinin neuropeptide, neurokinin B, in astrocytes and its role in cellular copper uptake. *J Inorg Biochem* 162: 319–325, 2016.
 309. Sharma DR, Sunkaria A, Wani WY, Sharma RK, Kandimalla RJ, Bal A, and Gill KD. Aluminium induced oxidative stress results in decreased mitochondrial biogenesis via modulation of PGC-1 α expression. *Toxicol Appl Pharmacol* 273: 365–380, 2013.
 310. Sheline CT, Zhu J, Zhang W, Shi C, and Cai AL. Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo. *Neurodegener Dis* 11: 49–58, 2013.
 311. Shen S, Li XF, Cullen WR, Weinfeld M, and Le XC. Arsenic binding to proteins. *Chem Rev* 113: 7769–7792, 2013.
 312. Sheng Y, Abreu IA, Cabelli DE, Maroney MJ, Miller AF, Teixeira M, and Valentine JS. Superoxide dismutases and superoxide reductases. *Chem Rev* 114: 3854–3918, 2014.
 313. Shi ZH, Nie G, Duan XL, Rouault T, Wu WS, Ning B, Zhang N, Chang YZ, and Zhao BL. Neuroprotective mechanism of mitochondrial ferritin on 6-hydroxydopamine-induced dopaminergic cell damage: implication for neuroprotection in Parkinson's disease. *Antioxid Redox Signal* 13: 783–796, 2010.
 314. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, and Murphy TH. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. *J Neurosci* 23: 3394–3406, 2003.
 315. Shila S, Kokilavani V, Subathra M, and Panneerselvam C. Brain regional responses in antioxidant system to α -lipoic acid in arsenic intoxicated rat. *Toxicology* 210: 25–36, 2005.
 316. Shila S, Subathra M, Devi MA, and Panneerselvam C. Arsenic intoxication-induced reduction of glutathione level and of the activity of related enzymes in rat brain regions: reversal by DL- α -lipoic acid. *Arch Toxicol* 79: 140–146, 2005.
 317. Shukalek CB, Swanlund DP, Rousseau RK, Weigl KE, Marensi V, Cole SP, and Leslie EM. Arsenic triglutathione [As(GS) $_3$] transport by multidrug resistance protein 1 (MRP1/ABCC1) is selectively modified by phosphorylation of Tyr920/Ser921 and glycosylation of Asn19/Asn23. *Mol Pharmacol* 90: 127–139, 2016.
 318. Simmons-Willis TA, Koh AS, Clarkson TW, and Ballatori N. Transport of a neurotoxicant by molecular mimicry: the methylmercury-L-cysteine complex is a substrate for human L-type large neutral amino acid transporter (LAT) 1 and LAT2. *Biochem J* 367: 239–246, 2002.
 319. Singh I, Sagare AP, Coma M, Perlmutter D, Gelein R, Bell RD, Deane RJ, Zhong E, Parisi M, Ciszewski J, Kasper RT, and Deane R. Low levels of copper disrupt

- brain amyloid-beta homeostasis by altering its production and clearance. *Proc Natl Acad Sci U S A* 110: 14771–14776, 2013.
320. Singh V, Gera R, Kushwaha R, Sharma AK, Patnaik S, and Ghosh D. Hijacking microglial glutathione by inorganic arsenic impels bystander death of immature neurons through extracellular cystine/glutamate imbalance. *Sci Rep* 6: 30601, 2016.
 321. Smith MA, Harris PL, Sayre LM, and Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. *Proc Natl Acad Sci U S A* 94: 9866–9868, 1997.
 322. Smith MR, Fernandes J, Go YM, and Jones DP. Redox dynamics of manganese as a mitochondrial life-death switch. *Biochem Biophys Res Commun* 482: 388–398, 2017.
 323. Sobotta MC, Liou W, Stocker S, Talwar D, Oehler M, Ruppert T, Scharf AN, and Dick TP. Peroxiredoxin-2 and STAT3 form a redox relay for H₂O₂ signaling. *Nat Chem Biol* 11: 64–70, 2015.
 324. Squitti R, Salustri C, Siotto M, Ventriglia M, Vernieri F, Lupoi D, Cassetta E, and Rossini PM. Ceruloplasmin/transferrin ratio changes in Alzheimer's disease. *Int J Alzheimers Dis* 2011: 231595, 2010.
 325. Squitti R, Simonelli I, Ventriglia M, Siotto M, Pasqualetti P, Rembach A, Doecke J, and Bush AI. Meta-analysis of serum non-ceruloplasmin copper in Alzheimer's disease. *J Alzheimers Dis* 38: 809–822, 2014.
 326. Squitti R, Ventriglia M, Gennarelli M, Colabufo NA, El Idrissi IG, Bucossi S, Mariani S, Rongioletti M, Zanetti O, Congiu C, Rossini PM, and Bonvicini C. Non-ceruloplasmin copper distincts subtypes in Alzheimer's disease: a genetic study of ATP7B frequency. *Mol Neurobiol* 54: 671–681, 2017.
 327. Steiger TK, Weiskopf N, and Bunzeck N. Iron level and myelin content in the ventral striatum predict memory performance in the aging brain. *J Neurosci* 36: 3552–3558, 2016.
 328. Storr SJ, Woolston CM, Zhang Y, and Martin SG. Redox environment, free radical, and oxidative DNA damage. *Antioxid Redox Signal* 18: 2399–2408, 2013.
 329. Stuber C, Morawski M, Schafer A, Labadie C, Wahnert M, Leuze C, Streicher M, Barapatre N, Reimann K, Geyer S, Spemann D, and Turner R. Myelin and iron concentration in the human brain: a quantitative study of MRI contrast. *Neuroimage* 93 (Pt 1): 95–106, 2014.
 330. Suazo M, Hodar C, Morgan C, Cerpa W, Cambiazo V, Inestrosa NC, and Gonzalez M. Overexpression of amyloid precursor protein increases copper content in HEK293 cells. *Biochem Biophys Res Commun* 382: 740–744, 2009.
 331. Sun Y, Jin K, Mao XO, Zhu Y, and Greenberg DA. Neuroglobin is up-regulated by and protects neurons from hypoxic-ischemic injury. *Proc Natl Acad Sci U S A* 98: 15306–15311, 2001.
 332. Tadepalle N, Koehler Y, Brandmann M, Meyer N, and Dringen R. Arsenite stimulates glutathione export and glycolytic flux in viable primary rat brain astrocytes. *Neurochem Int* 76: 1–11, 2014.
 333. Tai YK, Chew KC, Tan BW, Lim KL, and Soong TW. Iron mitigates DMT1-mediated manganese cytotoxicity via the ASK1-JNK signaling axis: implications of iron supplementation for manganese toxicity. *Sci Rep* 6: 21113, 2016.
 334. Takahashi M, Dore S, Ferris CD, Tomita T, Sawa A, Wolosker H, Borchelt DR, Iwatsubo T, Kim SH, Thinnakaran G, Sisodia SS, and Snyder SH. Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. *Neuron* 28: 461–473, 2000.
 335. Takeda A, Fuke S, Minami A, and Oku N. Role of zinc influx via AMPA/kainate receptor activation in metabotropic glutamate receptor-mediated calcium release. *J Neurosci Res* 85: 1310–1317, 2007.
 336. Tan J, Zhang T, Jiang L, Chi J, Hu D, Pan Q, Wang D, and Zhang Z. Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein. *J Biol Chem* 286: 29654–29662, 2011.
 337. Tang L, Zhang Y, Qian Z, and Shen X. The mechanism of Fe(2+)-initiated lipid peroxidation in liposomes: the dual function of ferrous ions, the roles of the pre-existing lipid peroxides and the lipid peroxy radical. *Biochem J* 352 (Pt 1): 27–36, 2000.
 338. Telianidis J, Hung YH, Materia S, and Fontaine SL. Role of the P-Type ATPases, ATP7A and ATP7B in brain copper homeostasis. *Front Aging Neurosci* 5: 44, 2013.
 339. Thevenod F. Catch me if you can! Novel aspects of cadmium transport in mammalian cells. *Biometals* 23: 857–875, 2010.
 340. Thomas DJ. Arsenolysis and thiol-dependent arsenate reduction. *Toxicol Sci* 117: 249–252, 2010.
 341. Tjälve H and Henriksson J. Uptake of metals in the brain via olfactory pathways. *Neurotoxicology* 20: 181–195, 1999.
 342. Todorich B, Pasquini JM, Garcia CI, Paez PM, and Connor JR. Oligodendrocytes and myelination: the role of iron. *Glia* 57: 467–478, 2009.
 343. Todorich B, Zhang X, Slagle-Webb B, Seaman WE, and Connor JR. Tim-2 is the receptor for H-ferritin on oligodendrocytes. *J Neurochem* 107: 1495–1505, 2008.
 344. Tokuda E, Okawa E, and Ono S. Dysregulation of intracellular copper trafficking pathway in a mouse model of mutant copper/zinc superoxide dismutase-linked familial amyotrophic lateral sclerosis. *J Neurochem* 111: 181–191, 2009.
 345. Tokuda E, Okawa E, Watanabe S, and Ono S. Overexpression of metallothionein-I, a copper-regulating protein, attenuates intracellular copper dyshomeostasis and extends lifespan in a mouse model of amyotrophic lateral sclerosis caused by mutant superoxide dismutase-1. *Hum Mol Genet* 23: 1271–1285, 2014.
 346. Tokuda E, Okawa E, Watanabe S, Ono S, and Marklund SL. Dysregulation of intracellular copper homeostasis is common to transgenic mice expressing human mutant superoxide dismutase-1s regardless of their copper-binding abilities. *Neurobiol Dis* 54: 308–319, 2013.
 347. Tolins M, Ruchirawat M, and Landrigan P. The developmental neurotoxicity of arsenic: cognitive and behavioral consequences of early life exposure. *Ann Glob Health* 80: 303–314, 2014.
 348. Torres-Avila M, Leal-Galicia P, Sanchez-Pena LC, Del Razo LM, and Gonsebatt ME. Arsenite induces aquaglyceroporin 9 expression in murine livers. *Environ Res* 110: 443–447, 2010.
 349. Toyama T, Shinkai Y, Yasutake A, Uchida K, Yamamoto M, and Kumagai Y. Isothiocyanates reduce mercury accumulation via an Nrf2-dependent mechanism during exposure of mice to methylmercury. *Environ Health Perspect* 119: 1117–1122, 2011.

350. Trujano-Ortiz LG, Gonzalez FJ, and Quintanar L. Redox cycling of copper-amyloid beta 1–16 peptide complexes is highly dependent on the coordination mode. *Inorg Chem* 54: 4–6, 2015.
351. Tulpule K, Robinson SR, Bishop GM, and Dringen R. Uptake of ferrous iron by cultured rat astrocytes. *J Neurosci Res* 88: 563–571, 2010.
352. Tuschl K, Mills PB, and Clayton PT. Manganese and the brain. *Int Rev Neurobiol* 110: 277–312, 2013.
353. United States. Agency for Toxic Substances and Disease Registry. *Toxicological Profile for Arsenic*. Atlanta, GA: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, 2007, p. 1 online resource (xx, 500 p.).
354. Urrutia P, Aguirre P, Esparza A, Tapia V, Mena NP, Arredondo M, Gonzalez-Billault C, and Nunez MT. Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. *J Neurochem* 126: 541–549, 2013.
355. Valko M, Jomova K, Rhodes CJ, Kuca K, and Musilek K. Redox- and non-redox-metal-induced formation of free radicals and their role in human disease. *Arch Toxicol* 90: 1–37, 2016.
356. Vanoevelen J, Dode L, Van Baelen K, Fairclough RJ, Missiaen L, Raeymaekers L, and Wuytack F. The secretory pathway $\text{Ca}^{2+}/\text{Mn}^{2+}$ -ATPase 2 is a Golgi-localized pump with high affinity for Ca^{2+} ions. *J Biol Chem* 280: 22800–22808, 2005.
357. Venderova K and Park DS. Programmed cell death in Parkinson's disease. *Cold Spring Harb Perspect Med* 2: a009365, 2012.
358. Ventriglia M, Brewer GJ, Simonelli I, Mariani S, Siotto M, Bucossi S, and Squitti R. Zinc in Alzheimer's disease: a meta-analysis of serum, plasma, and cerebrospinal fluid studies. *J Alzheimers Dis* 46: 75–87, 2015.
359. Verstraeten SV, Aimo L, and Oteiza PI. Aluminium and lead: molecular mechanisms of brain toxicity. *Arch Toxicol* 82: 789–802, 2008.
360. Vidal R, Miravalle L, Gao X, Barbeito AG, Baraibar MA, Hekmatyar SK, Widel M, Bansal N, Delisle MB, and Ghetti B. Expression of a mutant form of the ferritin light chain gene induces neurodegeneration and iron overload in transgenic mice. *J Neurosci* 28: 60–67, 2008.
361. Villar-Pique A, Lopes da Fonseca T, Sant'Anna R, Szego EM, Fonseca-Ornelas L, Pinho R, Carija A, Gerhardt E, Masaracchia C, Abad Gonzalez E, Rossetti G, Carloni P, Fernandez CO, Foguel D, Milosevic I, Zweckstetter M, Ventura S, and Outeiro TF. Environmental and genetic factors support the dissociation between alpha-synuclein aggregation and toxicity. *Proc Natl Acad Sci U S A* 113: E6506–E6515, 2016.
362. Wakabayashi K, Tanji K, Mori F, and Takahashi H. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. *Neuropathology* 27: 494–506, 2007.
363. Wang B and Du Y. Cadmium and its neurotoxic effects. *Oxid Med Cell Longev* 2013: 898034, 2013.
364. Wang H, Wang M, Wang B, Li M, Chen H, Yu X, Yang K, Chai Z, Zhao Y, and Feng W. Immunogold labeling and X-ray fluorescence microscopy reveal enrichment ratios of Cu and Zn, metabolism of APP and amyloid-beta plaque formation in a mouse model of Alzheimer's disease. *Metallomics* 4: 1113–1118, 2012.
365. Wang JY, Zhuang QQ, Zhu LB, Zhu H, Li T, Li R, Chen SF, Huang CP, Zhang X, and Zhu JH. Meta-analysis of brain iron levels of Parkinson's disease patients determined by postmortem and MRI measurements. *Sci Rep* 6: 36669, 2016.
366. Wang L and Gallagher EP. Role of Nrf2 antioxidant defense in mitigating cadmium-induced oxidative stress in the olfactory system of zebrafish. *Toxicol Appl Pharmacol* 266: 177–186, 2013.
367. Wang Q, Luo W, Zhang W, Dai Z, Chen Y, and Chen J. Iron supplementation protects against lead-induced apoptosis through MAPK pathway in weanling rat cortex. *Neurotoxicology* 28: 850–859, 2007.
368. Wang X, Liu J, Zhu H, Tejima E, Tsuji K, Murata Y, Atochin DN, Huang PL, Zhang C, and Lo EH. Effects of neuroglobin overexpression on acute brain injury and long-term outcomes after focal cerebral ischemia. *Stroke* 39: 1869–1874, 2008.
369. Wang X, Mori T, Sumii T, and Lo EH. Hemoglobin-induced cytotoxicity in rat cerebral cortical neurons: caspase activation and oxidative stress. *Stroke* 33: 1882–1888, 2002.
370. Wasserman GA, Liu X, Loiacono NJ, Kline J, Factor-Litvak P, van Geen A, Mey JL, Levy D, Abramson R, Schwartz A, and Graziano JH. A cross-sectional study of well water arsenic and child IQ in Maine schoolchildren. *Environ Health* 13: 23, 2014.
371. Wasserman GA, Liu X, Parvez F, Ahsan H, Factor-Litvak P, Kline J, van Geen A, Slavkovich V, Loiacono NJ, Levy D, Cheng Z, and Graziano JH. Water arsenic exposure and intellectual function in 6-year-old children in Arai-hazar, Bangladesh. *Environ Health Perspect* 115: 285–289, 2007.
372. Watanabe T and Hirano S. Metabolism of arsenic and its toxicological relevance. *Arch Toxicol* 87: 969–979, 2013.
373. Watt NT, Taylor DR, Kerrigan TL, Griffiths HH, Rushworth JV, Whitehouse IJ, and Hooper NM. Prion protein facilitates uptake of zinc into neuronal cells. *Nat Commun* 3: 1134, 2012.
374. Wezynfeld NE, Stefaniak E, Stachucy K, Drozd A, Plonka D, Drew SC, Krezel A, and Bal W. Resistance of Cu(Abeta4–16) to copper capture by metallothionein-3 supports a function for the Abeta4–42 peptide as a synaptic Cu(II) scavenger. *Angew Chem Int Ed Engl* 55: 8235–8238, 2016.
375. White AR, Reyes R, Mercer JF, Camakaris J, Zheng H, Bush AI, Multhaup G, Beyreuther K, Masters CL, and Cappai R. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. *Brain Res* 842: 439–444, 1999.
376. WHO. *Childhood Lead Poisoning*. World Health Organization Press, 2010. <http://www.who.int/ceh/publications/leadguidance.pdf>
377. Willhite CC, Karyakina NA, Yokel RA, Yenugadhati N, Wisniewski TM, Arnold IM, Momoli F, and Krewski D. Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. *Crit Rev Toxicol* 44 (Suppl 4): 1–80, 2014.
378. Wu CY, Steffen J, and Eide DJ. Cytosolic superoxide dismutase (SOD1) is critical for tolerating the oxidative stress of zinc deficiency in yeast. *PLoS One* 4: e7061, 2009.
379. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, Harry J, Rice DC, Maloney B, Chen D, Lahiri DK, and Zawia NH. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to

- environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. *J Neurosci* 28: 3–9, 2008.
380. Wu WS, Zhao YS, Shi ZH, Chang SY, Nie GJ, Duan XL, Zhao SM, Wu Q, Yang ZL, Zhao BL, and Chang YZ. Mitochondrial ferritin attenuates beta-amyloid-induced neurotoxicity: reduction in oxidative damage through the Erk/P38 mitogen-activated protein kinase pathways. *Antioxid Redox Signal* 18: 158–169, 2013.
 381. Xiao G, Fan Q, Wang X, and Zhou B. Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding. *Proc Natl Acad Sci U S A* 110: 14995–15000, 2013.
 382. Yamauchi H, Kaise T, and Yamamura Y. Metabolism and excretion of orally administered arsenobetaine in the hamster. *Bull Environ Contam Toxicol* 36: 350–355, 1986.
 383. Yang X, Wang B, Zeng H, Cai C, Hu Q, Cai S, Xu L, Meng X, and Zou F. Role of the mitochondrial Ca(2+)-uniporter in Pb(2+)-induced oxidative stress in human neuroblastoma cells. *Brain Res* 1575: 12–21, 2014.
 384. Ye F, Li X, Li F, Li J, Chang W, Yuan J, and Chen J. Cyclosporin A protects against Lead neurotoxicity through inhibiting mitochondrial permeability transition pore opening in nerve cells. *Neurotoxicology* 57: 203–213, 2016.
 385. Yin Z, Jiang H, Syversen T, Rocha JB, Farina M, and Aschner M. The methylmercury-L-cysteine conjugate is a substrate for the L-type large neutral amino acid transporter. *J Neurochem* 107: 1083–1090, 2008.
 386. Yokel RA, Wilson M, Harris WR, and Halestrap AP. Aluminum citrate uptake by immortalized brain endothelial cells: implications for its blood-brain barrier transport. *Brain Res* 930: 101–110, 2002.
 387. Yoshida M, Watanabe C, Horie K, Satoh M, Sawada M, and Shimada A. Neurobehavioral changes in metallothionein-null mice prenatally exposed to mercury vapor. *Toxicol Lett* 155: 361–368, 2005.
 388. Yoshino Y, Yuan B, Kaise T, Takeichi M, Tanaka S, Hirano T, Kroetz DL, and Toyoda H. Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes. *Toxicol Appl Pharmacol* 257: 198–208, 2011.
 389. You H, Tsutsui S, Hameed S, Kannanayakal TJ, Chen L, Xia P, Engbers JD, Lipton SA, Stys PK, and Zamponi GW. Abeta neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. *Proc Natl Acad Sci U S A* 109: 1737–1742, 2012.
 390. Yu WH, Lukiw WJ, Bergeron C, Niznik HB, and Fraser PE. Metallothionein III is reduced in Alzheimer's disease. *Brain Res* 894: 37–45, 2001.
 391. Yu X, Song N, Guo X, Jiang H, Zhang H, and Xie J. Differences in vulnerability of neurons and astrocytes to heme oxygenase-1 modulation: implications for mitochondrial ferritin. *Sci Rep* 6: 24200, 2016.
 392. Zamora PL, Rockenbauer A, and Villamena FA. Radical model of arsenic(III) toxicity: theoretical and EPR spin trapping studies. *Chem Res Toxicol* 27: 765–774, 2014.
 393. Zhang HN, Yang L, Ling JY, Czajkowsky DM, Wang JF, Zhang XW, Zhou YM, Ge F, Yang MK, Xiong Q, Guo SJ, Le HY, Wu SF, Yan W, Liu B, Zhu H, Chen Z, and Tao SC. Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic. *Proc Natl Acad Sci U S A* 112: 15084–15089, 2015.
 394. Zhang Y, Duan X, Li J, Zhao S, Li W, Zhao L, Li W, Nie H, Sun G, and Li B. Inorganic arsenic induces NRF2-regulated antioxidant defenses in both cerebral cortex and hippocampus in vivo. *Neurochem Res* 41: 2119–2128, 2016.
 395. Zhao F, Liao Y, Jin Y, Li G, Lv X, and Sun G. Effects of arsenite on glutamate metabolism in primary cultured astrocytes. *Toxicol In Vitro* 26: 24–31, 2012.
 396. Zhou X, Cooper KL, Sun X, Liu KJ, and Hudson LG. Selective sensitization of zinc finger protein oxidation by reactive oxygen species through arsenic binding. *J Biol Chem* 290: 18361–18369, 2015.
 397. Zhou X, Sun X, Mobarak C, Gandolfi AJ, Burchiel SW, Hudson LG, and Liu KJ. Differential binding of monomethylarsonous acid compared to arsenite and arsenic trioxide with zinc finger peptides and proteins. *Chem Res Toxicol* 27: 690–698, 2014.
 398. Zille M, Karuppagounder SS, Chen Y, Gough PJ, Bertin J, Finger J, Milner TA, Jonas EA, and Ratan RR. Neuronal death after hemorrhagic stroke in vitro and in vivo shares features of ferroptosis and necroptosis. *Stroke* 48: 1033–1043, 2017.
 399. Zimmermann LT, Santos DB, Naime AA, Leal RB, Dorea JG, Barbosa F, Jr., Aschner M, Rocha JB, and Farina M. Comparative study on methyl- and ethylmercury-induced toxicity in C6 glioma cells and the potential role of LAT-1 in mediating mercurial-thiol complexes uptake. *Neurotoxicology* 38: 1–8, 2013.
 400. Zucca FA, Segura-Aguilar J, Ferrari E, Munoz P, Paris I, Sulzer D, Sarna T, Casella L, and Zecca L. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. *Prog Neurobiol* 155: 96–119, 2017.

Address correspondence to:

Dr. Rodrigo Franco

Redox Biology Center and School of Veterinary Medicine

and Biomedical Sciences

University of Nebraska–Lincoln

114 VBS 0905

Lincoln, NE 68583

E-mail: rfrancocruz2@unl.edu

Prof. María E. Gonsebatt

Departamento de Medicina Genómica y

Toxicología Ambiental

Instituto de Investigaciones Biomédicas

Universidad Nacional Autónoma de México

Apartado Postal 70228

México City 04510

México

E-mail: margen@unam.mx

Dr. Liliana Quintanar

Departamento de Química

Centro de Investigación y de

Estudios Avanzados (CINVESTAV)

Av. Instituto Politécnico Nacional 2508

Apartado Postal 07360

México City 07360

México

E-mail: lilianaq@cinvestav.mx

Date of first submission to ARS Central, July 6, 2017; date of final revised submission, February 1, 2018; date of acceptance, February 3, 2018.

Abbreviations Used

$A\beta$ = amyloid beta
 AD = Alzheimer's disease
 AdoMet = S-adenosylmethionine
 Al = aluminum
 ALA = aminolevulinic acid
 ALAD = δ -aminolevulinic acid dehydratase
 $AlO_2^{\bullet-}$ = aluminum superoxide radicals
 ALS = amyotrophic lateral sclerosis
 AMPAR = α -amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor
 APP = amyloid precursor protein
 AQP = aqua(glycerol)porin
 As = arsenic
 AS3MT = arsenite methyltransferase
 AsIII = arsenite +3
 As(SG)₃ = arsenic triglutathione
 AsV = arsenate +5
 Atox1 = antioxidant protein 1
 ATP7A = ATPase copper transporting alpha
 ATP7B = ATPase copper transporting beta
 BBB = blood-brain barrier
 BLL = blood lead levels
 Ca = calcium
 CaM = Ca^{2+} /calmodulin
 CCS1 = copper chaperone for superoxide dismutase 1
 Cd = cadmium
 CNS = central nervous system
 CO₂ = carbon dioxide
 COX = cytochrome C oxidase
 Cp = ceruloplasmin
 CSF = cerebrospinal fluid
 CTR1 = copper transporter 1
 Cu = copper
 Cu⁺ = cuprous ion
 Cu²⁺ = cupric ion
 Cys = cysteine
 DA = dopamine
 Dcytb = duodenal cytochrome b
 Dexas1 = Ras-related dexamethasone induced 1
 DLA = dihydrolipoamide or dihydrolipoic acid
 DMAIII = dimethylarsinous acid
 DMAV = dimethylarsinic acid
 DMSA = 2,3-dimercaptosuccinic acid
 DMT1 = divalent metal transporter 1
 EAAT = excitatory amino acid transporter
 ER = endoplasmic reticulum
 EtHg or C₂H₅Hg = ethylmercury
 FBXL5 = F-box/LRR-repeat protein
 Fe = iron
 Fe²⁺ = ferrous
 Fe³⁺ = ferric
 Fpn = ferroportin
 Ft = ferritin
 FtMt = mitochondrial ferritin
 GAPDH = glyceraldehyde 3-phosphate dehydrogenase
 GCL = γ -glutamate-cysteine ligase
 Glu = glutamate
 GLUT = glucose transporters

GPX = glutathione peroxidases
 GR = glutathione reductase
 Grxs = glutaredoxins
 GS = glutamine synthetase
 GSH = glutathione
 GSSG = glutathione disulfide
 GST = glutathione-S transferase
 H₂O₂ = hydrogen peroxide
 Hb = hemoglobin
 HD = Huntington's disease
 H-Ft = heavy-ferritin
 Hg = mercury
 Hg⁰ = elemental or metallic Hg
 Hg¹⁺ = inorganic mercurous ions
 Hg²⁺ = inorganic mercuric ions
 HNE = 4-hydroxy-2-nonenal
 HO = heme oxygenase
 Hp = hephaestin
 Htt = huntingtin
 iAs = inorganic As
 iAsV-3-P-glycerate = 1-arsenato-3-phospho-Dglycerate
 IDP = intrinsically disordered protein
 IQ = intelligence quotient
 IRP = iron regulatory proteins
 K = potassium
 Keap1 = kelch-like ECH-associated protein 1
 LAT = L-type neutral amino acid transporter
 L-Ft = light-ferritin
 LTP = long-term potentiation
 MCU = mitochondrial Ca^{2+} uniporter
 MDA = malondialdehyde
 MeHg or CH₃Hg = methylmercury
 Met = methionine
 Mfrn2 = mitoferrin-2
 Mg = magnesium
 MMAIII = monomethylarsonous acid
 MMAV = monomethylarsonic acid or arsonate
 Mn = manganese
 MRE = metal response element
 mRNA = messenger RNA
 MRPs = multidrug resistance proteins
 MT = metallothionein
 MTF1 = metal-responsive transcription factor-1
 Na = sodium
 NaAsO₂ = sodium arsenite
 NADPH = nicotinamide adenine dinucleotide phosphate
 NBIA = neurodegeneration with brain iron accumulation
 NKB = neurokinin B
 NMDAR = glutamate/N-methyl-D-aspartate receptor
 NO[•] = nitric oxide
 NOS = nitric oxide synthase
 NOX = NADPH oxidases
 Nrf1/2 = nuclear factor erythroid-2-related factor 1 or 2
 O₂ = molecular oxygen
 O₂^{•-} = superoxide anion radical
 •OH = hydroxyl radical
 OONO⁻ = peroxynitrite

Abbreviations Used (Cont.)

Pb = lead
PD = Parkinson's disease
PNS = peripheral nervous system
polyQ = polyglutamine
ppb = parts per billion
PrP^C = cellular prion protein
Prxs = peroxiredoxins
RNS = reactive nitrogen species
ROS = reactive oxygen species
RyR = ryanodine receptor
S = sulfur
sAPP = soluble fragment of APP
SCO = cytochrome c oxidase assembly protein
sCp = soluble ceruloplasmin
SDR2 = stromal cell-derived receptor
Se = selenium

SLC30A10/hZnT1 = solute carrier family 30 member 10 or human Zn transporter 1
SN = substantia nigra
SOD = superoxide dismutase
SPCA = secretory pathway Ca²⁺ ATPase
Steap2 = six transmembrane epithelial antigen of the prostate 2
Tf = transferrin
TfR = transferrin receptor
Trxs = thioredoxins
Tyr = tyrosine
xCT = cystine/glutamate exchanger system
ZIP = Zrt-(Zn-regulated transporter)- or Irt (Fe-regulated transporter)-like proteins
Zn = zinc
ZnT = zinc transporters